Biogen (BIIB)

Company ID: 116 | CIK: 0000875045
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-K data

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Clinical trial commitments (backlog)

No 10-K data

Manufacturing capacity (capacity)

Independent Contractors (contractors)

No 10-Q data

Common stockholders of record (customers)

No 10-Q data

Employees (headcount)

Inventory (inventory_units)

No 10-K data

AVONEX sales volume growth (other)

No 10-K data

Accounts receivable (other)

No 10-K data

Accounts receivable overdue (other)

No 10-K data

Accumulated deficit (other)

No 10-K data

Allowance rate (other)

No 10-K data

Allowances as % of gross revenue (other)

No 10-K data

Allowances as percent of gross product revenues (other)

No 10-K data

B-cell NHL patient population (other)

No 10-Q data

Cambridge facility committed (other)

No 10-K data

Cancellable CRO commitments (other)

No 10-K data

Cancellable future CRO commitments (other)

No 10-K data

Capitalized inventory (other)

No 10-K data

Cash and cash equivalents (other)

No 10-K data

Cash and investments (other)

No 10-K data

Cash and marketable securities (other)

No 10-K data

Cash and securities (other)

No 10-K data

Cash and securities portfolio (other)

No 10-K data

Cash, cash equivalents and marketable securities (other)

No 10-K data

Commercial products marketed (other)

No 10-K data

Common Stock Outstanding (other)

Common shares outstanding (other)

No 10-K data

Common stock outstanding (other)

No 10-K data

Common stock shares outstanding (other)

No 10-Q data

Construction commitments (other)

No 10-K data

Construction in progress (other)

No 10-K data

Construction in progress - Solothurn facility (other)

No 10-K data

Construction investment (other)

No 10-K data

Construction investment — Oceanside manufacturing facility (other)

No 10-K data

Construction investment — San Diego campus (other)

No 10-K data

Construction spend to date (other)

No 10-K data

Contingent milestone payments (other)

No 10-K data

Convertible preferred shares outstanding (other)

No 10-K data

Copromotion profits (other)

No 10-K data

Cost of sales percentage (other)

No 10-K data

Cost of shares repurchased (other)

No 10-K data

Cost savings target (other)

No 10-K data

Countries marketing AVONEX (other)

No 10-Q data

Countries with AVONEX (other)

No 10-Q data

Countries with AVONEX marketed (other)

No 10-Q data

Countries with AVONEX sales (other)

No 10-Q data

Countries with distribution (other)

No 10-Q data

Countries with marketed products (other)

No 10-Q data

Cumulative Fumapharm product sales (other)

No 10-K data

Cumulative Fumapharm sales (other)

No 10-K data

Deferred TYSABRI revenue (other)

No 10-K data

Deferred revenue (other)

No 10-K data

Director-level minority representation (other)

No 10-Q data

Director-level women (other)

No 10-Q data

Director-level women representation (other)

No 10-Q data

Director-level women share (other)

No 10-Q data

Discount and allowance rate (other)

No 10-K data

Discount and allowance reserves (other)

Discounts and allowances (other)

Discounts and allowances rate (other)

No 10-K data

Distribution channel inventory (other)

No 10-Q data

Effective tax rate (other)

Employee turnover rate (other)

No 10-Q data

Ethnic or racial minority representation (other)

No 10-Q data

Ethnic/racial minority representation in US manager-level+ roles (other)

No 10-Q data

Expected TYSABRI returns (other)

No 10-K data

Federal net operating loss carryforwards (other)

No 10-K data

Fit for Growth expense savings (other)

No 10-K data

Fumapharm cumulative sales (other)

No 10-K data

Fumarate U.S. volume growth (other)

No 10-K data

Future milestone payments (other)

No 10-K data

GAZYVA U.S. volume growth (other)

No 10-K data

GAZYVA sales volume growth (other)

No 10-K data

Genentech Y2K contingency plan (other)

No 10-K data

Genentech milestone payments recognized (other)

No 10-K data

Global Director-level and above held by women (other)

No 10-Q data

Global distribution network coverage (other)

No 10-Q data

Gross margin on product sales (other)

No 10-K data

Gross operating expense savings (other)

No 10-Q data

Gross product revenues (other)

No 10-K data

Gross savings target (other)

No 10-K data

Hillerod facility commitment (other)

No 10-K data

Hillerod facility committed (other)

No 10-K data

Hillerod facility payments (other)

No 10-K data

Hillerod facility phase 2 commitment (other)

No 10-K data

Interferon U.S. volume growth (other)

No 10-K data

Inventory (other)

No 10-K data

Inventory balance (other)

No 10-K data

Inventory in distribution channel (other)

No 10-Q data

Inventory value (other)

No 10-K data

Inventory write-down (other)

No 10-K data

Inventory write-downs (other)

No 10-K data

Ionis shares held (other)

No 10-K data

Issued U.S. patents (other)

No 10-Q data

Land acquired (other)

No 10-K data

Lecanemab inventory (other)

No 10-K data

Manager-level ethnic/racial minorities (other)

No 10-Q data

Manager-level minorities (other)

No 10-Q data

Manager-level minority share (other)

No 10-Q data

Manufacturing facility commitment (other)

No 10-K data

Manufacturing facility commitments (other)

No 10-K data

Manufacturing facility paid (other)

No 10-K data

Manufacturing site acreage (other)

No 10-Q data

Marketed products (other)

Merger costs capitalized (other)

No 10-K data

Minority representation (other)

No 10-Q data

Net operating loss carryforwards (other)

No 10-K data

Net savings target (other)

No 10-K data

New patient switch rate (other)

No 10-K data

New patients switching therapy (other)

No 10-Q data

Number of Reportable Segments (other)

Oceanside facility committed (other)

No 10-K data

Operating expense savings target (other)

No 10-K data

Orphan drug designations (other)

No 10-K data

Outstanding equity awards (other)

No 10-Q data

Overdue accounts receivable (other)

No 10-K data

PML cases (other)

No 10-K data

Pension liability (other)

No 10-K data

Phase III overall response rate (other)

No 10-Q data

Pipeline Products (other)

No 10-Q data

Pipeline products (other)

No 10-K data

Pipeline products in Phase 2 or beyond (other)

Planned workforce reduction (other)

No 10-Q data

Post-marketing study concepts (other)

No 10-Q data

Post-marketing trials authorized (other)

No 10-Q data

Potential milestone payments (other)

No 10-K data

Product returns rate (other)

No 10-K data

Product revenue (other)

No 10-K data

Programs in Phase 3 trials (other)

No 10-Q data

R&D expense ratio (other)

No 10-K data

RITUXAN U.S. in-market sales (other)

No 10-K data

RITUXAN U.S. net sales (other)

No 10-K data

RITUXAN U.S. volume growth (other)

No 10-K data

RITUXAN US Net Sales (other)

No 10-K data

RITUXAN US net sales (other)

No 10-K data

RITUXAN copromotion product revenues (other)

No 10-K data

RITUXAN copromotion profits (other)

No 10-K data

RITUXAN in-market net sales (other)

No 10-Q data

RITUXAN profit share (other)

No 10-K data

Real estate footprint reduction (other)

No 10-K data

Registration-stage candidates (other)

No 10-K data

Registrational indications (other)

No 10-K data

Registrational trial product indications (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Repurchase authorization remaining (other)

No 10-K data

Research and development costs (other)

No 10-Q data

Reserves for discounts and allowances (other)

No 10-K data

Restricted stock forfeited (other)

No 10-K data

Restructuring cost savings (other)

No 10-K data

Restructuring reserve (other)

No 10-K data

Restructuring reserve balance (other)

No 10-K data

Revenue reductions (other)

No 10-K data

Revenue reserves percent of gross (other)

No 10-K data

Rituxan Net Sales (other)

No 10-K data

Rituxan U.S. net sales (other)

No 10-Q data

Rituxan US Net Sales (other)

No 10-K data

Rituxan US net sales (other)

Rituxan net sales (other)

No 10-K data

Rituxan post-marketing study concepts (other)

No 10-Q data

SPINRAZA U.S. volume growth (other)

No 10-K data

SPINRAZA rest of world volume growth (other)

No 10-K data

Sales allowances reserve (other)

No 10-K data

Sales volume growth (other)

No 10-K data

Samsung Bioepis ownership (other)

No 10-K data

Samsung Bioepis ownership stake (other)

No 10-K data

Senior notes potential cash outflow (other)

No 10-K data

Share of copromotion profits (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Share repurchases (other)

No 10-Q data

Share-based compensation expense (other)

No 10-K data

Shareholders of record (other)

No 10-Q data

Shares Outstanding (other)

No 10-K data

Shares available for future issuance (other)

No 10-Q data

Shares available for repurchase (other)

No 10-K data

Shares outstanding (other)

Shares repurchased (other)

Stock Price High (other)

No 10-K data

Stock Price Low (other)

No 10-K data

Stock options outstanding (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

TYSABRI MS approvals (other)

No 10-Q data

TYSABRI Rest of World sales volume growth (other)

No 10-K data

TYSABRI U.S. net sales (other)

No 10-K data

TYSABRI US net sales (other)

No 10-K data

TYSABRI US sales volume growth (other)

No 10-K data

TYSABRI deferred revenue (other)

No 10-K data

TYSABRI deferred revenue (Italy) (other)

No 10-K data

TYSABRI in-market net sales (other)

No 10-Q data

TYSABRI in-market sales (other)

TYSABRI inventory (other)

No 10-K data

TYSABRI net sales (other)

No 10-K data

TYSABRI run rate (other)

No 10-K data

TYSABRI sales returns allowance (other)

No 10-K data

TYSABRI sales volume growth (other)

No 10-K data

TYSABRI units expected to be returned (other)

No 10-K data

TYSABRI written-off inventory (other)

No 10-K data

TYSABRI written-off inventory used (other)

No 10-K data

Total assets (other)

No 10-K data

Total equity (other)

No 10-K data

Total inventory (other)

No 10-K data

Total liabilities (other)

No 10-K data

Total reserves for discounts and allowances (other)

No 10-K data

Treasury shares authorized (other)

No 10-K data

Treasury shares repurchased (other)

No 10-K data

Treasury stock repurchased (other)

No 10-K data

U.K. revenue share (other)

No 10-K data

U.S. Manager-level and above held by ethnic or racial minorities (other)

No 10-Q data

U.S. patent applications (other)

No 10-K data

U.S. patents allowed (other)

No 10-K data

U.S. patents issued (other)

No 10-K data

U.S. patents owned (other)

No 10-K data

US minority manager representation (other)

No 10-Q data

US patent applications (other)

No 10-K data

US patents (other)

No 10-K data

US patents allowed (other)

No 10-K data

US patents issued (other)

No 10-K data

US patents issued and allowed (other)

No 10-K data

Unit sales volume change (other)

No 10-K data

Unit sales volume growth (other)

No 10-K data

United States patent applications (other)

No 10-K data

Unrecognized share-based compensation (other)

No 10-K data

Venture capital funding commitment (other)

No 10-K data

Vernalis shares held (other)

No 10-K data

Weighted-average diluted shares (other)

No 10-K data

Wholesale price increase (other)

No 10-K data

Wholesaler inventory (other)

No 10-K data

Women in director-level and above positions (other)

No 10-Q data

Women in director-level roles (other)

No 10-Q data

Women in leadership (other)

No 10-Q data

Women representation (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Workforce reduction (other)

Year 2000 remediation progress (other)

No 10-K data

Yttrium-90 escrow deposits (other)

No 10-K data

Yttrium-90 escrow funded (other)

No 10-K data

Yttrium-90 escrow payments (other)

No 10-K data

ZEVALIN Net Sales (other)

No 10-K data

ZEVALIN product sales (other)

No 10-K data

Phase III trial patients entered (patients)

Licensed biologics manufacturing sites (properties)

No 10-Q data

Renewable energy (renewable_energy_pct)

No 10-Q data

PML cases (safety_incidents)

No 10-K data

Office square footage (square_footage)

Rituxan Net Sales (units_shipped)

No 10-K data

AVONEX patients (users)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No 10-Q data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30acquisition_additioncompleted2026-05-142026-05-14United StatesSpecialized Immunology (SYFOVRE, EMPAVELI)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Apellis acquisition closed 2026-05-14; headcount added not quantified. Apellis unvested equity awards converted to $416.3M cash awards, of which ~$116.0M recognized at close for employees terminated upon acquisition.
2026-06-30restructuringin_progress2026-05-14Not specifiedEnterprise (Apellis integration)USD 153 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Net pre-tax restructuring charges for Q2 and YTD 2026; primarily employee severance and acceleration of double-trigger bonus payments. Employee count not disclosed.
2026-06-30restructuringin_progress2026-01-01Not specifiedEnterprise (Fit for Growth program)USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2026 expense of $7.9M against workforce-reduction reserve; reserve balance $35.9M at 2026-06-30. Employee count for current-period actions not disclosed; program historically reduced ~1,400 net headcount through 2025.
2026-06-30restructuringin_progress2026-05-14GlobalApellis IntegrationUSD 153 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recognized $153.2M net pre-tax restructuring charges for Q2 2026, primarily employee severance and accelerated bonus payments. Employee count not disclosed.
2026-06-30restructuringin_progress2023-01-01GlobalFit for Growth ProgramUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recognized $7.9M in restructuring charges for Q2 2026 related to severance costs. Program initiated in 2023 with ~1,400 net headcount reductions total.
2026-06-30restructuringin_progressUSD 165,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressApellis Integration [Member]USD 153,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressWorkforce Reduction [Member]USD 165,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progress1,4002023 Cost Saving Initiatives [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2026-03-31restructuringin_progress2023-01-01GlobalCompany-wideUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2026 severance charges under Fit for Growth; reserve $13.6M at quarter-end. Program-wide totals (1,400 net headcount reductions, ~$320M charges) are cumulative through end of 2025, not current-period.
2026-03-31acquisition_additionannounced2026-03-31United StatesCompany-wideUSD 5,600 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement for Apellis at $41.00/share (~$5.6B) plus CVRs up to $4.00/share; no headcount disclosed. Funded with ~$3.6B cash and ~$2.0B bank loans.
2026-03-31acquisition_additioncompleted2025-11-012026-01-31United StatesR&D / ManufacturingUSD 85 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed Nov 2025; $35M contingent payment made Jan 2026 upon FDA approval. No headcount disclosed.
2026-03-31acquisition_additionannounced2026-04-01Greater ChinaR&D / CommercialUSD 100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2026 agreement for felzartamab China rights; $100M upfront to be expensed in Q2 2026. No headcount disclosed.
2026-03-31restructuringin_progress2023-01-01GlobalVariousUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023. Q1 2026 charges of $7.9M related to severance costs. Program generated ~$1.0B gross savings by end of 2025 with net headcount reductions of ~1,400 employees historically.
2026-03-31restructuringin_progressUSD 7,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressWorkforce Reduction [Member]USD 7,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progress1,4002023 Cost Saving Initiatives [Member]restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2025-12-31restructuringin_progress1,4002023-01-01GlobalCompany-wideUSD 49 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: net headcount reductions of approximately 1,400 employees and total restructuring charges of approximately $320.0 million by end of 2025. FY2025-specific charges were $48.7M severance ($57.4M total charges); FY2025 employees affected not separately disclosed. Program generated approximately $1.0 billion in gross operating expense savings by end of 2025.
2025-12-31acquisition_additioncompleted2025-11-302025-11-30United StatesR&D / Clinical-stage biotechnologyUSD 85 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Completed November 2025; accounted for as an asset acquisition. Total consideration of approximately $85.0 million recorded to acquired IPR&D, upfront and milestone expense. Headcount added not disclosed.
2025-12-31divestiture_reductioncompleted2025-03-312025-07-31United StatesBiosimilarsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of U.S. regulatory and commercial rights for TOFIDENCE to Organon completed March 2025; payment of approximately $51.0 million received July 2025. Headcount removed not disclosed.
2025-12-31divestiture_reductioncompleted2025-10-312026-01-31EuropeBiosimilars / Ophthalmologydiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of remaining European commercial rights completed October 2025; payment of $28.0 million received November 2025. Transfer of BYOOVIZ rights back to Samsung Bioepis effective January 2026. Headcount removed not disclosed.
2025-12-31restructuringcompleted1,4002023-01-012025-12-31GlobalAll FunctionsUSD 320 (millions)Item 1. Business - Human Capital
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 Fit for Growth program included net headcount reductions of approximately 1,400 employees. Total restructuring charges incurred were approximately $320.0 million by the end of 2025.
2025-12-31restructuringin_progress1,4002023-01-012025-12-31GlobalAll FunctionsUSD 320 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2023 Fit for Growth program. Net headcount reductions of approximately 1,400 employees. Total restructuring charges of approximately $320.0 million incurred by the end of 2025.
2025-12-31restructuringin_progressUSD 48,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD -1,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 10,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 48,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progress1,4002023 Cost Saving Initiatives [Member]USD 57,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 6,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 14,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD -700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressReata Integration [Member]USD 20,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressWorkforce Reduction [Member]USD 48,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progress1,4002023-01-012025-12-31GlobalCompany-wideUSD 310 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fit for Growth program initiated in 2023; net headcount reductions of approximately 1,400 employees; total charges substantially achieved as of September 30, 2025; expected to generate ~$1.0B gross opex savings by end of 2025
2025-09-30acquisition_additionannounced2025-09-012025-12-31United StatesR&D / Medical DevicesUSD 85 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Alcyone Therapeutics; $85.0M upfront cash payment upon closing; to be accounted for as asset acquisition; headcount not disclosed
2025-09-30restructuringin_progress2023-01-012025-12-31GlobalAll functionsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023. Estimated net headcount reductions of approximately 1,400 employees. Total expected restructuring charges of approximately $310.0 million, substantially achieved as of September 30, 2025. Q3 2025 charges were $7.4 million.
2025-09-30restructuringcompleted2023-09-012023-12-31GlobalReata IntegrationUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reata integration plan. Estimated total integration charges of approximately $35.0 million related to severance and employment costs, substantially incurred during 2023. Q3 2025 charges were $5.4 million, primarily accelerated depreciation and other costs.
2025-09-30restructuringin_progressUSD 7,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 7,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progress1,4002023 Cost Saving Initiatives [Member]USD 8,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressReata Integration [Member]USD 5,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD 7,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progress1,40020232025-12-31GlobalCompany-wideUSD 300 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program targets ~$1.0B gross operating expense savings by end of 2025; expected total charges $300–310M, with ~$300M cumulative as of 2025-06-30. Headcount figure is net reduction estimate for full program, not a quarterly delta.
2025-06-30restructuringcompleted2023-092023-12-31United StatesReata acquisition integrationUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated total integration charges of ~$35M for severance and employment costs, substantially incurred during 2023. Employee count not disclosed.
2025-06-30restructuringin_progress2023-01-012025-12-31GlobalMultipleUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023. Total estimated headcount reduction of approx. 1,400 employees. Q2 2025 charges of $0.9M include accelerated depreciation and other costs; no severance costs recorded in Q2. Cumulative charges approx. $300M.
2025-06-30restructuringin_progress2023-09-01GlobalMultipleUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reata integration plan. Q2 2025 charges of $5.8M primarily accelerated depreciation and other costs. Total estimated integration charges approx. $35M.
2025-06-30restructuringin_progressUSD -700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD -1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progress1,4002023 Cost Saving Initiatives [Member]USD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressReata Integration [Member]USD 5,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD -700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progress2023-01-012025-12-31GlobalCompany-wideUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fit for Growth program initiated 2023; cumulative net headcount reductions of ~1,400 employees and cumulative charges of ~$300M through 2025-03-31. Q1 2025 severance charge was $35.3M. Program targets ~$1.0B gross opex savings by end of 2025. No quarterly employee-affected count disclosed.
2025-03-31restructuringin_progress2023-09-01United StatesReata integrationUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reata acquisition integration; total estimated integration charges ~$35M, substantially incurred during 2023. Q1 2025 restructuring charge was a $(0.2)M credit. No employee count disclosed for the quarter.
2025-03-31restructuringin_progress1,4002023-01-012025-12-31GlobalAll functionsUSD 300 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in 2023. Estimated net headcount reductions of approximately 1,400 employees. Total expected restructuring charges range from $300.0 million to $310.0 million. Cumulative charges incurred as of March 31, 2025, totaled approximately $300.0 million.
2025-03-31restructuringin_progressUSD 35,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD -3,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 5,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 35,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progress1,4002023 Cost Saving Initiatives [Member]USD 36,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD -200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressReata Integration [Member]USD 3,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progress1,00020232025-12-31GlobalCompany-wideUSD 50 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year cost-savings program initiated in 2023; the ~1,000 net headcount reduction is a program-level estimate, not FY2024-specific. FY2024 charges of $49.7M comprise $24.2M severance and $25.5M accelerated depreciation and other costs. Program targets approximately $1.0B in gross operating expense savings by the end of 2025, with total expected restructuring charges of $260.0–280.0M.
2024-12-31restructuringin_progress2023-09Company-wideUSD 22 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year integration plan implemented following the September 2023 Reata acquisition; estimated total integration charges of approximately $35.0M for severance and employment costs were substantially incurred during 2023. FY2024 charges of $21.6M comprise $3.4M severance and $18.2M accelerated depreciation and other costs.
2024-12-31acquisition_additioncompleted2024-07-02business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Human Immunology Biosciences, Inc. completed July 2, 2024 for approximately $1.15B in cash plus up to $650.0M in potential milestone payments; the number of employees added to the workforce is not disclosed.
2024-12-31restructuringin_progress2024-07USD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Integration plan implemented following the July 2024 HI-Bio acquisition, designed to realize operating synergies through cost savings and avoidance; approximately $2.6M of severance and employment costs were reflected in restructuring charges for the year ended December 31, 2024.
2024-12-31restructuringin_progress2023-01-012025-12-31GlobalCompany-wideUSD 50 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program initiated 2023; cumulative net headcount reductions of approximately 1,000 employees and total expected charges of $260-280M. FY2024 charges were $49.7M ($24.2M severance, $25.5M accelerated depreciation/other). Program expected to generate ~$1.0B gross savings by end of 2025.
2024-12-31acquisition_additioncompleted2024-07-022024-07-02United StatesSpecialized Immunologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Human Immunology Biosciences for $1.15B cash plus up to $650M contingent milestones. Headcount added not disclosed. HI-Bio operations had immaterial impact on results for FY2024.
2024-12-31restructuringcompleted2024-07-022024-12-31United StatesSpecialized ImmunologyUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Integration plan following HI-Bio acquisition; severance and employment costs incurred in FY2024. Employee count not disclosed.
2024-12-31restructuringin_progress2023-09-262024-12-31United StatesRare Disease / CorporateUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Reata integration charges in FY2024 totaled $21.6M ($3.4M severance, $18.2M accelerated depreciation/other). Total estimated integration charges ~$35M, substantially incurred in 2023. Employee count not disclosed.
2024-12-31restructuringin_progress1,0002023-01-012025-12-31GlobalGlobalUSD 260 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Initiated in 2023. Expected to generate $1.0 billion in gross operating expense savings by end of 2025. Estimated net headcount reductions of approximately 1,000 employees. Expected restructuring charges ranging from $260.0 million to $280.0 million. Charges incurred in 2024 were $49.7 million.
2024-12-31restructuringcompleted2023-09-262023-12-31GlobalReata IntegrationUSD 30 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Integration plan following Reata acquisition. Estimated total integration charges of approximately $35.0 million related to severance and employment costs. Severance and employment costs were substantially incurred during 2023. $30.4 million incurred in 2023.
2024-12-31restructuringcompleted2024-07-022024-12-31GlobalHI-Bio IntegrationUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Integration plan following HI-Bio acquisition. Incurred approximately $2.6 million of severance and employment costs in 2024.
2024-12-31restructuringcompleted2021-12-012026-12-31Global2022 Cost Saving InitiativesUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Initiated in 2022. Charges related to these initiatives were substantially incurred during 2022 with remaining payments expected to be made through 2026. $0.4 million incurred in 2023.
2024-12-31restructuringin_progress1,00020232025-12-31GlobalAll FunctionsUSD 260 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023. Estimated net headcount reductions of approximately 1,000 employees. Expected total restructuring charges ranging from $260.0 million to $280.0 million. Program expected to generate $1.0 billion in gross operating expense savings by end of 2025.
2024-12-31acquisition_additioncompleted2024-07-022024-07-02GlobalImmunologybusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of HI-Bio completed July 2, 2024. Specific headcount added not disclosed in filing.
2024-12-31restructuringcompleted2024-07-022024-12-31GlobalImmunologyUSD 3 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		HI-Bio integration plan. Incurred approximately $2.6 million of severance and employment costs in 2024. Specific headcount affected not disclosed.
2024-12-31restructuringin_progressUSD 30,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 13,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 11,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 24,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progress2023 Cost Saving Initiatives [Member]USD 49,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 6,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 11,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 3,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressReata Integration [Member]USD 21,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressEmployee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD -2,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressAccelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 2,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressWorkforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressWorkforce Reduction [Member]USD 30,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progress1,0002023-07-012025-12-31GlobalCompany-wideUSD 270 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fit for Growth program; charges estimated at $260–280M total; expected to generate ~$1.0B gross operating expense savings by end of 2025. Reserve balance $40.2M at 2024-09-30.
2024-09-30acquisition_additioncompleted2024-07-022024-07-02United StatesImmunology / R&DUSD 56 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		HI-Bio acquisition closed 2024-07-02; $56.4M recognized as share-based compensation for accelerated vesting of HI-Bio employee equity awards ($42.5M R&D, $13.9M SG&A). Headcount added not disclosed.
2024-09-30restructuringin_progress2024-07-022024-12-31GlobalCompany-wideUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		HI-Bio integration plan; ~$1.5M severance and employment costs incurred in Q3 2024.
2024-09-30restructuringin_progress2023-09-262024-12-31GlobalCompany-wideUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reata integration; total charges estimated at $35–40M, substantially incurred during 2023. Q3 2024 charges were $5.2M (severance $0.7M, accelerated depreciation/other $4.5M).
2024-09-30restructuringin_progress2023-07-012025-12-31GlobalGlobalUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated July 2023. Expected to generate $1.0 billion in gross operating expense savings by end of 2025. Estimated net headcount reductions of approximately 1,000 employees. Total expected restructuring charges $260.0 million to $280.0 million. Q3 2024 charges: $4.6 million severance, $12.6 million accelerated depreciation/other.
2024-09-30restructuringin_progress2023-09-262024-12-31GlobalReata IntegrationUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan following Reata acquisition. Estimated total integration charges $35.0 million to $40.0 million related to severance and employment costs, expected to be paid by end of 2024. Q3 2024 charges: $0.7 million severance, $4.5 million accelerated depreciation/other.
2024-09-30restructuringcompleted2024-07-022024-09-30GlobalHI-Bio IntegrationUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan following HI-Bio acquisition. Incurred approximately $1.5 million of severance and employment costs reflected in restructuring charges for Q3 2024.
2024-09-30restructuringin_progressUSD 6,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 9,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 3,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 4,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progress1,0002023 Cost Saving Initiatives [Member]USD 17,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 2,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressReata Integration [Member]USD 5,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD 6,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progress1,0002023-072025-12-31GlobalCompany-wideUSD 270 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced July 2023; filer discloses expected total charges of approximately $260.0M to $280.0M (midpoint shown) and net headcount reductions of approximately 1,000 employees; expected to generate ~$1.0B gross operating expense savings by end of 2025. Quarterly severance expense of $6.3M in Q2 2024 and $15.6M YTD 2024; restructuring reserve of $40.2M at 2024-06-30. No employees-affected count specific to the current quarter is disclosed.
2024-06-30restructuringin_progress2023-09-262024-12-31GlobalReata integrationUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan following the September 26, 2023 Reata acquisition; expected total integration charges of approximately $35.0M to $40.0M (midpoint shown) for severance and employment costs, payable by end of 2024; substantially incurred during 2023. Q2 2024 total charges of $5.1M and YTD 2024 charges of $11.8M. No employee count disclosed.
2024-06-30acquisition_additioncompleted2024-07-022024-07-02United StatesImmunology (Human Immunology Biosciences)USD 1,150 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: acquisition of HI-Bio completed July 2, 2024 for ~$1.15B upfront plus up to $650.0M in contingent milestones; to be recognized in Q3 2024. No headcount added disclosed.
2024-06-30restructuringin_progress2023-07-012025-12-31GlobalAll functionsUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated July 2023. Expected to generate $1.0B gross operating expense savings by end of 2025. Estimated net headcount reductions of approximately 1,000 employees. Total expected restructuring charges $260M-$280M. Q2 2024 charges: $6.3M severance, $4.2M accelerated depreciation/other.
2024-06-30restructuringin_progress2023-09-262024-12-31GlobalReata IntegrationUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan following Reata acquisition. Estimated total integration charges $35M-$40M related to severance and employment costs, expected to be paid by end of 2024. Q2 2024 charges: $0.3M severance, $4.8M accelerated depreciation/other.
2024-06-30restructuringin_progressUSD 6,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 6,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progress1,0002023 Cost Saving Initiatives [Member]USD 10,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 3,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressReata Integration [Member]USD 5,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD 6,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progress1,0002023-07-012025-12-31GlobalCompany-wideUSD 270 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced July 2023; approximately 1,000 net headcount reductions. Expected charges of $260.0M–$280.0M (midpoint shown); ~$1.0B gross opex savings targeted by end of 2025. Q1 2024 charges totaled $15.6M.
2024-03-31restructuringin_progress2023-09-262024-12-31United StatesReata integrationUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration severance/employment charges estimated at $35.0M–$40.0M (midpoint shown), substantially incurred in 2023, expected paid by end of 2024. Q1 2024 charges totaled $6.7M. No employee count disclosed.
2024-03-31acquisition_additioncompleted2023-09-262023-09-26United StatesRare disease (SKYCLARYS)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reata acquisition closed September 26, 2023; no headcount added through the acquisition is disclosed in this filing.
2024-03-31restructuringin_progress2023-07-012025-12-31GlobalMultipleUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated July 2023. Expected to generate $1.0B gross operating expense savings by end of 2025. Estimated net headcount reductions of approx. 1,000 employees. Total expected charges $260M-$280M. Q1 2024 charges: $9.3M severance, $6.3M accelerated depreciation/other.
2024-03-31restructuringin_progress2023-09-262024-12-31GlobalMultipleUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan following Reata acquisition. Estimated total integration charges $35M-$40M related to severance and employment costs. Q1 2024 charges: $2.2M severance, $4.5M accelerated depreciation/other.
2024-03-31restructuringin_progressUSD 11,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 4,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 9,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progress1,0002023 Cost Saving Initiatives [Member]USD 15,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Reata Integration [Member]USD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member] / Reata Integration [Member]USD 2,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressRestructuring Charges [Member] / Reata Integration [Member]USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressReata Integration [Member]USD 6,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress1,0002023USD 213 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fit for Growth program initiated in 2023: approximately 1,000 net headcount reductions targeted. Expected total restructuring charges of $260.0M–$280.0M; $212.5M incurred in FY2023 ($153.4M severance, $59.1M accelerated depreciation and other). Program targets ~$1.0B gross / ~$800.0M net operating expense savings by 2025, some reinvested.
2023-12-31restructuringin_progress20232024USD 30 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Reata integration plan implemented after the September 26, 2023 acquisition close, aimed at cost savings/avoidance. Primarily severance; approximately $30.4M net pre-tax charge recognized in FY2023, with severance payments expected to be completed by end of 2024. Employee count not disclosed.
2023-12-31acquisition_additioncompleted2023-09-262023-09-26business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Reata Pharmaceuticals completed September 26, 2023; Reata employee headcount added not disclosed. Approximately $983.9M paid for Reata outstanding equity awards (inclusive of employer taxes), of which $393.4M recognized as post-acquisition compensation ($196.4M SG&A, $197.0M R&D).
2023-12-31restructuringin_progress1,0002023-01-012025-12-31GlobalCompany-wideUSD 270 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Net headcount reductions of approximately 1,000 employees; expected restructuring charges range from $260.0M to $280.0M (midpoint shown). Program expected to generate ~$1.0B gross / $800M net operating expense savings by 2025. Charges incurred in FY2023 totaled $212.5M across SG&A, R&D, and restructuring lines.
2023-12-31acquisition_additioncompleted2023-09-262023-09-26GlobalRare Disease / Neurologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Reata completed 2023-09-26 for ~$7.19B total consideration. Headcount added not quantified in filing. Reata integration restructuring charges of ~$30.4M recognized in FY2023 for employee severance.
2023-12-31restructuringcompleted2023-09-262024-12-31GlobalReata integrationUSD 30 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Integration plan severance charges of ~$30.4M net pre-tax recognized in FY2023; payments expected by end of 2024. Headcount affected not disclosed.
2023-12-31othercompleted2023-11-01GlobalR&D — ADUHELM / Neurimmune collaborationUSD 60 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Termination of Neurimmune collaboration and discontinuation of ADUHELM; close-out costs of ~$60.0M recorded in R&D expense. Headcount impact not quantified.
2023-12-31othercompleted2023-09-01GlobalR&D — EMBARK study (aducanumab)USD 43 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Termination costs of ~$43.0M recorded in R&D expense. Headcount impact not quantified.
2023-12-31othercompleted2023-04-01GlobalR&D — BIIB093 programUSD 13 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Close-out costs of ~$13.2M recorded in R&D expense. Headcount impact not quantified.
2023-12-31divestiture_reductionannounced2024-01-012025-01-01GlobalCommercial — FAMPYRA (Acorda collaboration)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Biogen notified Acorda of termination effective January 1, 2025; Acorda regains global commercialization rights to FAMPYRA. Announced after fiscal year-end but before filing date. Headcount impact not quantified.
2023-12-31restructuringin_progress1,0002023-01-012025-12-31GlobalGlobalUSD 270 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fit for Growth program initiated in 2023. Estimated net headcount reductions of approximately 1,000 employees. Expected restructuring charges ranging from $260.0 million to $280.0 million. Charges incurred in 2023 totaled $212.5 million (Note 4).
2023-12-31restructuringcompleted2023-09-262024-12-31GlobalGlobalUSD 30 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Reata integration plan implemented following acquisition close. Recognized approximately $30.4 million of net pre-tax restructuring charges related to employee severance costs in 2023. Payments expected by end of 2024.
2023-12-31restructuringin_progress1,0002023-01-012025-12-31GlobalAll FunctionsUSD 270 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023. Estimated net headcount reductions of approximately 1,000 employees. Expected restructuring charges ranging from $260.0 million to $280.0 million.
2023-12-31acquisition_additioncompleted2023-09-262023-09-26GlobalAll FunctionsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Reata Pharmaceuticals completed on September 26, 2023. Specific headcount added not explicitly disclosed in the narrative, but equity-based compensation of $393.4 million recognized for Reata employees.
2023-12-31restructuringin_progressUSD 218,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 23,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 1,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 188,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progress1,0002023 Cost Saving Initiatives [Member]USD 212,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr		Expected positions to be eliminated
2023-12-31restructuringin_progressRestructuring Charges [Member] / Employee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD -2,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressRestructuring Charges [Member] / Accelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 2,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressRestructuring Charges [Member] / Workforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressEmployee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD -2,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressAccelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 2,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressWorkforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressWorkforce Reduction [Member]USD 181,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress1,0002023-07-312025-12-31GlobalCompany-wideUSD 115 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Net headcount reduction of approximately 1,000 employees; program targets ~$1.0B gross operating expense savings by 2025. Charge shown is total 2023 Fit for Growth charges for the nine months ended 2023-09-30 (severance $62.6M plus accelerated depreciation/other $51.9M); Q3-only charges were $61.1M. Program announced July 2023.
2023-09-30acquisition_additioncompleted2023-07-282023-09-26United StatesRare disease / neurology (Reata Pharmaceuticals)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Reata completed 2023-09-26 for ~$6.6B cash plus ~$983.9M for outstanding equity awards; no employee headcount added disclosed. Reata results consolidated from acquisition date.
2023-09-30restructuringin_progress2023-09-262024-12-31GlobalReata integrationUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Integration plan expected to incur ~$30.0M of restructuring charges in 2023, primarily severance payable by end of 2024; ~$21.0M of net pre-tax charges recognized in Q3 and 9M 2023. Employee count not disclosed.
2023-09-30restructuringin_progress1,0002023-07-012025-12-31GlobalAll functionsUSD 115 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fit for Growth program initiated in 2023; estimated net headcount reduction of approx. 1,000 employees. YTD charges of $114.5M include severance and accelerated depreciation.
2023-09-30restructuringin_progress2023-09-262024-12-31GlobalReata IntegrationUSD 21 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Integration plan following Reata acquisition; expected total charges of approx. $30.0M in 2023, primarily severance. YTD charges of $21.0M recognized.
2023-09-30restructuringin_progressUSD 76,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 5,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progress1,0002023 Cost Saving Initiatives [Member]USD 61,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr		Expected positions to be eliminated
2023-09-30restructuringin_progressRestructuring Charges [Member] / Employee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressRestructuring Charges [Member] / Accelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressRestructuring Charges [Member] / Workforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressAccelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressWorkforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD 58,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progress2023Company-wide (SG&A, R&D and restructuring lines)USD 53 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fit for Growth cost-saving measures initiated during 2023; charges for six months ended 2023-06-30 were $53.4M total, including $24.9M severance and $28.5M accelerated depreciation/other. Restructuring reserve was $32.3M at 2023-06-30. No employee counts disclosed. Related to the July 2023 Fit for Growth program announcement below.
2023-06-30restructuringannounced1,0002023-072025MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter announcement (July 2023) of a Fit for Growth program targeting approximately $1.0B gross operating expense savings, with about $300M reinvested in launches and R&D, yielding roughly $700M net savings by 2025; includes net headcount reduction of approximately 1,000. Headcount figure is approximate and no total workforce figure is disclosed for percentage calculation.
2023-06-30restructuringin_progress2023-07-012025-12-31GlobalGlobalsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced in July 2023 (subsequent to quarter-end). Program expected to generate $1.0 billion in gross operating expense savings by 2025, including net headcount reduction of approximately 1,000.
2023-06-30restructuringin_progress2023-01-01GlobalGlobalUSD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred for the three months ended June 30, 2023, under the 'Fit for Growth' initiative. Includes $17.8 million in severance costs and $28.5 million in accelerated depreciation and other costs. Employee count not disclosed.
2023-06-30restructuringin_progress2023-01-01GlobalGlobalUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred for the six months ended June 30, 2023, under the 'Fit for Growth' initiative. Includes $24.9 million in severance costs and $28.5 million in accelerated depreciation and other costs. Employee count not disclosed.
2023-06-30restructuringin_progress2022-01-012026-12-31GlobalGlobalUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred for the three months ended June 30, 2023, related to 2022 initiatives. Remaining payments expected through 2026. Employee count not disclosed.
2023-06-30restructuringin_progress2022-01-012026-12-31GlobalGlobalUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred for the six months ended June 30, 2023, related to 2022 initiatives. Remaining payments expected through 2026. Employee count not disclosed.
2023-06-30restructuringin_progressUSD 34,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / 2023 Cost Saving Initiatives [Member]USD 11,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / 2023 Cost Saving Initiatives [Member]USD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressRestructuring Charges [Member] / 2023 Cost Saving Initiatives [Member]USD 34,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progress2023 Cost Saving Initiatives [Member]USD 46,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressRestructuring Charges [Member] / Employee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressRestructuring Charges [Member] / Accelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressRestructuring Charges [Member] / Workforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member] / 2022 Cost Saving Initiatives [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressAccelerated Depreciation And Other Costs [Member] / 2022 Cost Saving Initiatives [Member]USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressWorkforce Reduction [Member] / 2022 Cost Saving Initiatives [Member]USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member] / 2023 and 2022 Cost Saving Initiatives [Member]USD 17,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progress2021-12GlobalCompany-wide (workforce reductions, ADUHELM commercial infrastructure, real estate consolidation, SG&A and R&D efficiencies)USD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2021 and expanded May 2022; total estimated charges ~$135.0M, substantially incurred during 2022. Q1 2023 net pre-tax restructuring charges of $9.6M (of which ~$7.1M employee severance). Restructuring reserve of $28.0M at 2023-03-31; payments expected through 2026. No employee headcount affected is disclosed in this filing.
2023-03-31plant_closurecompleted2022-03United States (Durham, North Carolina)Patient services officerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company ceased use of the facility in March 2022, expediting ~$10.4M of depreciation in Q1 2022; lease assigned to a third party in May 2022. No employee count disclosed; included here as a disclosed facility-level workforce action under the same program.
2023-03-31restructuringin_progress2022-05-012026-12-31GlobalSelling, general and administrative; Research and developmentUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of 2022 Cost Saving Initiatives announced in Dec 2021 and May 2022. Q1 2023 charges of $9.6M included $7.1M in employee severance costs. Total estimated charges ~$135M. Payments expected through 2026.
2023-03-31restructuringin_progressUSD 9,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressMinimum [Member]USD 135,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressWorkforce Reduction [Member]USD 7,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progress2021-122026Company-wide: workforce reductions; elimination of commercial ADUHELM infrastructure; real estate consolidation; SG&A and R&D efficiency gainsUSD 131 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program initially announced December 2021 and expanded May 2022, targeting roughly $1.0 billion of expense savings. FY2022 net pre-tax charges of $131.1M, of which $112.6M was employee severance tied to 2022 workforce reductions; $78.0M of severance was paid during the year, leaving a $35.9M reserve at December 31, 2022 expected to be paid through 2026. Also includes a $5.3M gain on the 300 Binney Street lease modification, $10.4M accelerated depreciation from ceasing use of a Durham, NC office, and $13.2M other restructuring costs. No count of employees affected was disclosed.
2022-12-31restructuringin_progress2021-12-012026-12-31GlobalCompany-wide (workforce reductions, ADUHELM commercial infrastructure, real estate consolidation, SG&A and R&D efficiency)USD 131 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2021 and expanded May 2022; expected to yield approximately $1.0 billion in expense savings. FY2022 net pre-tax restructuring charges of $131.1M, of which $112.6M was employee severance. $35.9M remained in the restructuring reserve at 2022-12-31 with payments expected through 2026. Employees affected count not disclosed.
2022-12-31divestiture_reductioncompleted2022-04-012022-04-30South KoreaBiosimilars (Samsung Bioepis joint venture)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Biogen's 49.9% equity interest in Samsung Bioepis to Samsung BioLogics completed April 2022; no headcount impact quantified in the filing.
2022-12-31restructuringin_progress2022-05-012026-12-31GlobalSelling, general and administrative; Research and developmentUSD 131 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2022 Cost Saving Initiatives announced in December 2021 and May 2022. Estimated total restructuring charges of approximately $131.0 million, primarily related to severance. Payments expected to be made through 2026.
2022-12-31restructuringin_progress2022-05-012026-12-31GlobalVariousUSD 131 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in Dec 2021 and May 2022. Includes workforce reductions, elimination of ADUHELM infrastructure, and real estate consolidation. Total estimated charges of $131.0 million, primarily severance. Payments expected through 2026.
2022-12-31restructuringin_progressUSD 131,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressWorkforce Reduction [Member]USD 112,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progress2021-122022-12-31GlobalMultiple — workforce reductions, elimination of commercial ADUHELM infrastructure, real estate consolidation, SG&A and R&D operating efficienciesUSD 124 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced December 2021 with additional measures announced May 2022; no employee count disclosed. $124.1M net pre-tax charges recognized in nine months ended 2022-09-30 ($15.4M in Q3), of which $110.2M YTD was employee severance. Expected total charges of approximately $130.0M to $150.0M, substantially incurred and paid by end of 2022. Restructuring reserve was $40.2M at 2022-09-30. Includes $10.4M accelerated depreciation from ceasing use of a Durham, NC office, $8.8M other restructuring costs from a May 2022 lease assignment, and a $5.3M gain from the September 2022 partial termination of the 300 Binney Street, Cambridge, MA lease.
2022-09-30restructuringin_progress2022-05-012022-12-31GlobalGlobal Alzheimer's infrastructure, Selling, General & Administrative, Research & DevelopmentUSD 124 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2022 Cost Saving Initiatives announced in Dec 2021 and May 2022. Includes workforce reductions, elimination of ADUHELM commercial infrastructure, and real estate consolidation. YTD charges of $124.1M include $110.2M in severance. Expected to be substantially incurred and paid by end of 2022.
2022-09-30restructuringin_progressUSD 15,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressWorkforce Reduction [Member]USD 21,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progress2022-052022-12-31GlobalWorkforce reductions (primarily global Alzheimer's/ADUHELM commercial infrastructure), real estate consolidation, SG&A and R&D operating efficienciesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2022 cost saving initiatives announced December 2021 and May 2022; expected total charges of $130.0M-$150.0M, primarily severance, substantially incurred and paid by end of 2022. $70.6M recognized in Q2 2022 and $108.7M in six months ended June 30, 2022 (incl. $88.6M severance for six months, $10.4M accelerated depreciation, $9.7M other restructuring costs). Restructuring reserve $52.2M at June 30, 2022. Number of employees affected not disclosed.
2022-06-30restructuringin_progress2022-05-012022-12-31GlobalGlobal Alzheimer's infrastructure, Selling, General & Administrative, Research & DevelopmentUSD 109 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced in Dec 2021 and May 2022. Includes workforce reductions, elimination of ADUHELM commercial infrastructure, and real estate consolidation. Expected total charges $130M-$150M. Q2 2022 charges were $70.6M ($60.9M severance). YTD 2022 charges were $108.7M ($88.6M severance). Employee count affected not disclosed.
2022-06-30restructuringin_progressUSD 70,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressWorkforce Reduction [Member]USD 60,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progress2021-122022-12-31GlobalPrimarily global Alzheimer's infrastructure; also real estate consolidation and SG&A/R&D operating efficiencyUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2022 Cost Saving Initiatives announced Dec 2021 (expanded May 2022). Expected total charges $100–150M, primarily severance, substantially incurred and paid by end of 2022. Q1 2022 charges: $27.7M severance + $10.4M accelerated depreciation. No employee headcount affected disclosed. Restructuring reserve $21.5M at 3/31/22.
2022-03-31otherannounced2022-05-03GlobalExecutive leadershipsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company announced search for new CEO; current CEO Michel Vounatsos to continue serving during interim period.
2022-03-31restructuringin_progress2021-12-012022-12-31GlobalAlzheimer's infrastructure, Selling, General and Administrative, Research and DevelopmentUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Dec 2021 and May 2022. Includes $27.7M employee-related costs (severance) and $10.4M accelerated depreciation for Durham, NC office closure. Total expected charges $100M-$150M.
2022-03-31restructuringin_progressUSD 38,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressWorkforce Reduction [Member]USD 27,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31acquisition_additioncompleted2019-06-072019-06-07United Kingdom / United StatesOphthalmology research and developmentUSD 852 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total purchase price of $852.2 million; headcount added through the acquisition is not disclosed
2019-12-31divestiture_reductioncompleted2019-082019-08Hillerød, DenmarkBiologics manufacturing operationsUSD 55 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of subsidiary to FUJIFILM Corporation; pre-tax loss on divestiture of $55.3 million after a $40.2 million Q4 reduction; employees removed through the sale are not quantified
2019-12-31restructuringin_progressUSD 2 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-tax restructuring and other exit-related costs of $1.5 million recognized in 2019; employees affected, geography, and completion timeline are not disclosed
2019-12-31restructuringcompletedGlobalVariousUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax restructuring and other exit-related costs of $1.5 million recognized in 2019.
2019-12-31restructuringcompletedWorldwideUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Pre-tax restructuring and other exit-related costs of $1.5 million recognized in 2019. Employee count not disclosed.
2019-12-31divestiture_reductioncompleted2019-08-012019-08-01DenmarkManufacturingUSD 55 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of biologics manufacturing operations in Hillerød, Denmark to FUJIFILM in August 2019. Pre-tax loss of $55.3 million recognized. Employee count not explicitly disclosed.
2019-12-31restructuringin_progressUSD 1,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressUSD 0 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $0.3M in Q3 2019 and $1.5M YTD 2019 disclosed in income statement; no employee counts, geographies, or program details provided.
2019-09-30acquisition_additioncompleted2019-06-072019-06-07United KingdomOphthalmology R&Dbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Nightstar Therapeutics plc completed 2019-06-07 for $852.2M total purchase price; no employee headcount added disclosed.
2019-09-30divestiture_reductioncompleted2019-08-012019-08-01DenmarkBiologics manufacturing (Hillerød)USD 96 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Hillerød biologics manufacturing subsidiary to FUJIFILM completed 2019-08-01; pre-tax loss of $95.5M recognized; no employee headcount reduction disclosed.
2019-09-30restructuringcompleted2019-09-30DenmarkManufacturingUSD 0 (millions)financial_statements
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $0.3 million recorded for the three months ended Sept 30, 2019. Context suggests relation to Hillerød divestiture completed Aug 1, 2019, but specific employee count not disclosed.
2019-09-30acquisition_additioncompleted2019-06-07GlobalR&Dbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Nightstar Therapeutics plc completed June 7, 2019. Employee count not disclosed.
2019-09-30restructuringin_progressUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30acquisition_additioncompleted2019-06-072019-06-07United Kingdom / United StatesOphthalmology research and developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Nightstar Therapeutics plc completed June 7, 2019; headcount added not disclosed. Post-combination equity compensation of $26.2M expensed.
2019-06-30divestiture_reductionin_progress2019-03-012019-09-30Hillerød, DenmarkBiologics manufacturing operationsUSD 113 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Share purchase agreement with FUJIFILM for Hillerød manufacturing subsidiary; assets and liabilities classified as held for sale in February 2019. Pre-tax loss of $113.2M recorded for six months ended June 30, 2019. Employee count affected not disclosed.
2019-06-30restructuringin_progressUSD 1 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $1.2M for six months ended June 30, 2019 ($0.8M in Q2); no employee counts, program details, or completion dates disclosed in this filing.
2019-06-30restructuringin_progress2019-032019-09-30DenmarkManufacturingUSD 113 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Proposed divestiture of Hillerød manufacturing operations. Pre-tax loss of $113.2M recorded for six months ended June 30, 2019, including $120M adverse commitment obligation. Transaction expected to close in Q3 2019.
2019-06-30acquisition_additioncompleted2019-06-072019-06-07GlobalOphthalmologyUSD 852 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Nightstar Therapeutics plc completed June 7, 2019. Total purchase price $852.2M. Employee headcount not disclosed.
2019-06-30restructuringin_progressUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31divestiture_reductionin_progress2019-03-012019-12-31Hillerød, DenmarkBiologics manufacturing operationsUSD 116 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Share purchase agreement with FUJIFILM for the Hillerød biologics manufacturing subsidiary; assets and liabilities classified as held for sale in Feb 2019. Filing discloses a $115.5M pre-tax loss on assets/liabilities held for sale (part of a ~$174.6M total estimated loss including tax) but does not quantify employees affected.
2019-03-31restructuringin_progressUSD 0 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $0.4M recorded for the three months ended March 31, 2019; no employee counts, geographies, or completion timing disclosed in this filing.
2019-03-31restructuringin_progress2019-03-312019-12-31DenmarkManufacturingUSD 0 (millions)financial_statements
f5-10q / Qwen3.6-27B-Q8_0		Filing discloses $0.4 million in restructuring charges for Q1 2019. While the filing details a proposed divestiture of the Hillerød, Denmark manufacturing operations with a $115.5 million loss on assets held for sale, it does not explicitly quantify the number of employees affected by this divestiture or the restructuring charges.
2019-03-31restructuringin_progressUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progress2017-10-01GlobalCorporate / cross-functionalUSD 23 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2017 Corporate Strategy program; $22.9M total charges in FY2018 ($12.0M in restructuring charges, $10.9M in SG&A), primarily severance. Program targets redirecting up to $400M annually by 2020; employee headcount impact not disclosed.
2018-12-31divestiture_reductioncompleted2017-02-012017-02-01GlobalHemophilia business (Bioverativ)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-off of hemophilia business completed February 1, 2017; headcount transferred not disclosed. Included for context as it affects workforce totals.
2018-12-31plant_closurecompleted2016-06-012016-12-31United StatesManufacturing — Cambridge, MA and Somerville, MA facilitiesUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Prior-year action (2016); Cambridge biologics manufacturing facility and Somerville warehouse closed. Severance charges substantially paid by Q1 2017. No FY2018 activity.
2018-12-31restructuringin_progress2017-102020-12-31GlobalVariousUSD 12 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2017 Corporate Strategy program approved in Oct 2017 to streamline operations. $12.0 million in restructuring charges recognized in 2018 (primarily severance). Total non-recurring operating and capital expenditures expected to be approximately $135.0 million. Goal to redirect resources of up to $400.0 million annually by 2020. Employee count not explicitly disclosed for this action.
2018-12-31restructuringin_progress2017-102020-12-31WorldwideResearch and Development; Sales and MarketingUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2017 Corporate Strategy program. $12.0 million recognized in restructuring charges in 2018, primarily related to severance. Total non-recurring operating and capital expenditures expected to be approximately $135.0 million. Goal to redirect resources of up to $400.0 million annually by 2020. Employee count not explicitly disclosed for 2018 activity.
2018-12-31divestiture_reductioncompleted2017-02-012017-02-01WorldwideHemophilia Businessdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Spin-off of hemophilia business (Bioverativ) completed on February 1, 2017. While this occurred in the prior year, it is the primary driver of workforce composition changes referenced in 2018 MD&A regarding 'leaner and simpler operating model' and reallocation of resources. No specific headcount reduction attributed to this event in the 2018 fiscal year flow metrics.
2018-12-31restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressRestructuring Charges [Member] / 2017 Corporate Strategy [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2017 Corporate Strategy [Member]USD 10,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progress2017-102018-12-31GlobalCorporateUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2018 charges; primarily severance. No employee count disclosed. Total program cost up to $170M; charges expected substantially paid in cash by end of 2018.
2018-09-30restructuringin_progress2017-10-012018-12-31GlobalCorporateUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2017 Corporate Strategy program. Q3 2018 charges of $6.0M primarily related to severance. Expected to be substantially paid in cash by end of 2018.
2018-09-30restructuringin_progress2017-10-012018-12-31GlobalCorporateUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2017 Corporate Strategy program. YTD 2018 charges of $9.2M primarily related to severance. Expected to be substantially paid in cash by end of 2018.
2018-09-30restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progress2017 Corporate Strategy [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2017-10CorporateUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2017 Corporate Strategy program approved October 2017; six months 2018 charges of $3.2M primarily severance, substantially paid as of 2018-06-30. No employee count disclosed. Program contemplates up to $170.0M total non-recurring operating and capital expenditures, primarily in 2018.
2018-06-30restructuringin_progress2017-10-01USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2017 Corporate Strategy program; charges primarily related to severance. Program substantially paid as of June 30, 2018.
2018-06-30restructuringin_progress2017-10-01USD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2018 charges for 2017 Corporate Strategy program; primarily severance.
2018-06-30restructuringin_progressUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2017 Corporate Strategy [Member]USD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progress2017-10-012018-06-30GlobalCorporateUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2018 charge of $1.6M, primarily severance; program approved Oct 2017 with total non-recurring spend up to $170M. No employee count disclosed.
2018-03-31restructuringin_progress2017-10-012018-06-30GlobalCorporateUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2017 Corporate Strategy program. Charges primarily related to severance. Expected to be substantially incurred and paid by mid-2018.
2018-03-31restructuringin_progressUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progress2017 Corporate Strategy [Member]USD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progress2017-10GlobalCorporate-wideUSD 19 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		October 2017 program to streamline operations; $19.4M recognized in 2017 ($18.5M in SG&A, $0.9M in restructuring charges), primarily severance. Company expects up to $170.0M total non-recurring operating and capital expenditures, primarily in 2018, to redirect up to $400.0M annually by 2020. No employee count disclosed.
2017-12-31divestiture_reductioncompleted2017-02-01GlobalHemophilia business (Bioverativ Inc.)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Hemophilia business spun off as independent public company on February 1, 2017; results included through January 31, 2017. No headcount transferred disclosed.
2017-12-31restructuringin_progress2017-102020GlobalCorporate / OperationsUSD 170 (millions)Item 1. Business - 2017 Corporate Strategy
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		October 2017 corporate restructuring program to streamline operations. Total non-recurring operating and capital expenditures up to $170.0 million, primarily in 2018. Goal to redirect resources up to $400.0 million annually by 2020. Employee count not disclosed.
2017-12-31divestiture_reductioncompleted2017-02-012017-02-01GlobalHemophilia BusinessItem 1. Business - Hemophilia Spin-Off
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Spin-off of hemophilia business (Bioverativ Inc.) completed February 1, 2017. Employee count transferred not disclosed.
2017-12-31restructuringin_progress2017-102020-12-31WorldwideCorporate / OperationsUSD 170 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		October 2017 corporate restructuring program to streamline operations. Total non-recurring operating and capital expenditures up to $170.0 million, primarily in 2018. Goal to redirect resources by 2020. Employee count not disclosed.
2017-12-31restructuringcompleted2016-062017-03-31United StatesManufacturingUSD 7 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs related to employees separated in connection with ceasing manufacturing and vacating Cambridge, MA facility and Somerville, MA warehouse. Charges recognized in 2016, substantially incurred and paid by end of Q1 2017. Employee count not disclosed.
2017-12-31restructuringcompleted2015-102017-12-31WorldwideCorporate / PipelineUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2015 restructuring program (11% workforce reduction). $0.9 million restructuring charges recognized in 2017. Employee count for 2017 activity not disclosed.
2017-12-31restructuringin_progressUSD 900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressRestructuring Charges [Member] / 2017 Restructuring Charges [Member]USD 900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / 2017 Restructuring Charges [Member]USD 18,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progress2017 Restructuring Charges [Member]USD 19,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringannounced2017-10USD 170 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter program approved in October 2017 to streamline operations; up to $170.0M non-recurring operating and capital expenditures expected, primarily in 2018, with a goal of redirecting up to $400.0M annually by 2020. No employee count disclosed.
2017-09-30divestiture_reductioncompleted2017-02-012017-02-01GlobalHemophilia business (Bioverativ)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of hemophilia business completed 2017-02-01; net assets of $1,008.3M transferred and employees moved to Bioverativ, but no headcount figure is disclosed. Results reflect hemophilia operations only through 2017-01-31.
2017-09-30restructuringannounced2017-102018-12-31GlobalCorporateUSD 170 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Announced in October 2017 to streamline operations and reallocate resources. Expected non-recurring operating and capital expenditures up to $170.0 million, primarily in 2018. Employee count not disclosed.
2017-09-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30divestiture_reductioncompleted2017-02-01GlobalHemophilia business (Bioverativ)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of hemophilia business completed 2017-02-01; employees transferring to Bioverativ had unvested equity awards converted. No employee count disclosed; results include hemophilia business only through 2017-01-31.
2017-06-30acquisition_additioncompleted02017-05-15United StatesR&D — BIIB093 (CIRARA) asset purchase from Remedy PharmaceuticalsUSD 120 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition accounted for as purchase of IPR&D; filing states no employees were acquired from Remedy. $120.0M upfront recorded as acquired in-process R&D expense, not a severance charge.
2017-06-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31divestiture_reductioncompleted2017-02-01GlobalHemophilia business (Bioverativ)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of hemophilia business completed 2017-02-01; employees transferring to Bioverativ referenced but no headcount disclosed. Results include hemophilia business only through 2017-01-31.
2017-03-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progress2015-10-212016-12-31GlobalCorporate-wide; included termination of certain pipeline programsUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced October 21, 2015 with an 11% workforce reduction; charge shown is the FY2016 net restructuring charge only. Program substantially paid by end of 2016; reserve of $5.1M remained at year-end.
2016-12-31restructuringcompleted2016-07-012016-12-31GlobalCorporate-wide organizational realignment tied to hemophilia spin-offUSD 18 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Initiated in Q3 2016; charges primarily severance, substantially incurred and paid by end of 2016. Announcement date approximated to Q3 2016; exact date not disclosed.
2016-12-31plant_closurecompleted2016-06-012016-12-31Cambridge, MA and Somerville, MA, United StatesSmall-scale biologics manufacturing and warehouse operationsUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision to vacate announced June 2016; sublease to Brammer Bio completed December 2016. Charge is Q4 2016 severance for separated employees; separately, $45.5M of accelerated depreciation was recorded in cost of sales. Announcement date approximated to June 2016.
2016-12-31divestiture_reductionannounced2016-05-012017-02-01GlobalHemophilia business (Bioverativ Inc.)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-off of hemophilia business completed February 1, 2017; Bioverativ became an independent public company. Headcount transferred not disclosed. Announcement date approximated to May 2016.
2016-12-31restructuringcompleted2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2015 Corporate Restructuring program. Total net restructuring charges of $8.0 million recognized in 2016. Substantially incurred and paid by end of 2016.
2016-12-31restructuringcompleted2016-09-302016-12-31GlobalOrganizational RealignmentUSD 18 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2016 Organizational Changes. Charges totaling $17.7 million recognized in 2016 related to realigning organizational structure for hemophilia spin-off. Substantially incurred and paid by end of 2016.
2016-12-31plant_closurecompleted2016-06-302017-01-01Cambridge, MA and Somerville, MAManufacturingUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cessation of manufacturing at Cambridge, MA facility and vacating Somerville, MA warehouse. $7.4 million in severance costs for employees separated in connection with transaction. Substantially incurred and paid by end of Q1 2017.
2016-12-31restructuringcompleted2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2015 Cost Saving Initiatives. Announced Oct 2015. Included 11% workforce reduction and pipeline termination. $8.0M recognized in 2016. Substantially incurred and paid by end of 2016.
2016-12-31restructuringcompleted2016-07-012016-12-31GlobalOrganizational RealignmentUSD 18 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2016 Organizational Changes. Initiated Q3 2016 to realign structure for hemophilia spin-off. $17.7M recognized. Primarily severance. Substantially incurred and paid by end of 2016.
2016-12-31plant_closurecompleted2016-06-012017-03-31Cambridge, MA and Somerville, MAManufacturingUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cambridge Manufacturing Facility. Ceased manufacturing Dec 2016. Subleased to Brammer. $7.4M severance for separated employees recognized Q4 2016. Expected substantially incurred and paid by end of Q1 2017.
2016-12-31restructuringin_progressUSD 33,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressCambridge, MA [Member] / 2016 Restructuring Charges [Member]USD 7,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progress2015 Restructuring Charges [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progress2016 Restructuring Charges [Member]USD 17,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress11%2015-10-212016-12-31GlobalCorporate (includes pipeline program terminations)USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2015 corporate restructuring: 11% workforce reduction plus termination of certain pipeline programs; no absolute headcount disclosed. $8.1M net charges recognized in nine months ended 2016-09-30; reserve of $8.3M remains at quarter end; amounts expected substantially paid by end of 2016.
2016-09-30restructuringin_progress2016-12-31GlobalCorporate — organizational realignment ahead of hemophilia spin-offUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Initiated during Q3 2016 (no specific announcement date given); $13.2M charged in both the three and nine months ended 2016-09-30; total expected charges of approximately $20.0M, primarily severance, substantially incurred and paid by end of 2016. No employee count disclosed.
2016-09-30plant_closurein_progress2016-062016-12-31United States (Cambridge, MA and Somerville, MA)Manufacturing — small-scale biologics facility and warehouseUSD 32 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision in June 2016 to vacate 67,000 sq ft Cambridge manufacturing facility and 46,000 sq ft Somerville warehouse by end of 2016; associated workforce reduction not quantified. Charge shown is $31.5M of accelerated depreciation recorded in cost of sales for the nine months ended 2016-09-30 ($15.7M in Q3); asset carrying value ~$29.0M, remaining lease obligation $25.5M, no impairment recorded.
2016-09-30divestiture_reductionannounced2016-052017-03-31GlobalHemophilia business (ELOCTATE, ALPROLIX) — Bioverativ Inc. spin-offother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off announced May 2016, expected completion early 2017 subject to conditions; no headcount associated with the separation disclosed. Related 2016 organizational restructuring (separate record above) is driven in part by this transaction.
2016-09-30restructuringin_progress2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2015 corporate restructuring including 11% workforce reduction and pipeline termination. Net charge of $8.1M recognized for the nine months ended Sept 30, 2016. Expected to be substantially paid by end of 2016.
2016-09-30restructuringin_progress2016-07-012016-12-31GlobalOrganizational RealignmentUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 organizational changes to realign structure in anticipation of hemophilia business spin-off. Charges of $13.2M recognized for three and nine months ended Sept 30, 2016. Total expected charges approx $20.0M, primarily severance.
2016-09-30plant_closurein_progress2016-06-012016-12-31Cambridge, MA and Somerville, MAManufacturingUSD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Vacating and ceasing manufacturing in Cambridge, MA biologics facility and Somerville, MA warehouse. Recorded $31.5M additional depreciation for nine months ended Sept 30, 2016 due to shortened useful lives. No employee count disclosed.
2016-09-30restructuringin_progressUSD 11,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progress2015 Restructuring Charges [Member]USD -1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progress2016 Restructuring Charges [Member]USD 13,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progress11%2015-10-212016-12-31USD 105 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program included termination of certain pipeline programs and an 11% workforce reduction; absolute employee count not disclosed. Cash payments total approximately $120 million, of which $15.9 million related to previously accrued 2015 incentive compensation, yielding net expected charges of approximately $105 million. Charges of $0.0 million in Q2 2016 and $9.7 million YTD; restructuring reserve was $12.3 million at June 30, 2016. Amounts to be substantially paid by end of 2016.
2016-06-30plant_closureannounced2016-062016-12-31Cambridge, MA and Somerville, MA, United StatesManufacturing (small-scale biologics manufacturing facility and warehouse)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In June 2016 Biogen determined it intends to cease manufacturing in Cambridge, MA and vacate its 67,000 sq ft biologics facility and 46,000 sq ft Somerville warehouse by end of 2016, considering a sale of the facility; closure by December 31, 2016 if no sale. No employee count disclosed. Carrying value of associated assets approximately $43.0 million; remaining lease obligation $26.3 million; no impairment identified; $15.8 million of accelerated depreciation recorded in cost of sales due to shortened useful lives.
2016-06-30divestiture_reductionannounced2016-052017Hemophilia business (ELOCTATE and ALPROLIX)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In May 2016 Biogen announced intention to spin off its hemophilia business as an independent publicly traded company, expected to complete in early 2017 subject to Board approval, tax opinion and effectiveness of a Form 10 registration statement. No headcount associated with the spin-off disclosed; hemophilia results remain consolidated until completion.
2016-06-30restructuringin_progress11%2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Oct 2015. Includes 11% workforce reduction and pipeline termination. $9.7M charge recognized in Q2 2016. Total expected charges ~$105M.
2016-06-30plant_closureannounced2016-06-302016-12-31Cambridge, MA and Somerville, MAManufacturingUSD 16 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Intention to cease manufacturing and vacate facilities by end of 2016. $15.8M accelerated depreciation recorded. No specific headcount disclosed.
2016-06-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progress11%2015-10-212016-12-31USD 105 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program includes termination of certain pipeline programs and an 11% workforce reduction; no absolute headcount disclosed. Net expected restructuring charges ~$105M (cash payments ~$120M, including ~$15.9M accrued 2015 incentive compensation). Q1 2016 charge was $9.7M ($1.4M workforce reduction, $8.3M pipeline terminations); $93.4M recognized in Q4 2015. Reserve of $17.3M at 2016-03-31; amounts substantially incurred and to be substantially paid by end of 2016. Percent of workforce is as of the October 2015 announcement, not quarter-end.
2016-03-31restructuringin_progress11%2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Oct 21, 2015. Includes 11% workforce reduction and pipeline terminations. Q1 2016 charges: $1.4M workforce, $8.3M pipeline. Total expected net charges ~$105M.
2016-03-31restructuringin_progressUSD 9,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressContract Termination [Member]USD 8,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressEmployee Severance [Member]USD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progress11%2015-10-212016-12-31GlobalCorporate-wide; includes termination of certain pipeline programs (Phase 3 TECFIDERA in SPMS, anti-TWEAK in lupus nephritis, certain immunology and fibrosis research activities)USD 93 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Q4 2015 charge of $93.4M ($86.2M workforce reduction, $7.2M pipeline terminations). Total net expected charge $105M with ~$120M cash payments (incl. $15.9M previously accrued incentive comp), substantially incurred and paid by end of 2016. Expected to reduce annual operating expense run rate by ~$250M. Reserve at 2015-12-31 was $37.3M; $72.0M paid through year-end. 11% workforce reduction; absolute headcount not disclosed.
2015-12-31acquisition_additioncompleted2015-02-122015-02-12United KingdomResearch & Development (neuropathic pain)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding stock completed 2015-02-12; Biogen retained key Convergence employees. Headcount added not quantified. Total purchase price $474.6M.
2015-12-31restructuringin_progress11%2015-10-212016-12-31GlobalCorporate and Pipeline ProgramsUSD 93 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced October 21, 2015. Includes workforce reduction and discontinuation of certain programs. 11% reduction in workforce. $93.4 million charge recognized in Q4 2015. Expected to be substantially incurred and paid by end of 2016.
2015-12-31restructuringcompleted11%2015-10-212016-12-31WorldwideVariousUSD 93 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced October 21, 2015. Includes 11% workforce reduction and termination of certain pipeline programs. $93.4 million charge recognized in Q4 2015 ($86.2M workforce, $7.2M pipeline). Expected cash payments ~$120M, substantially incurred/paid by end of 2016.
2015-12-31restructuringin_progressUSD 93,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressContract Termination [Member]USD 7,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member]USD 86,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringannounced11%2015-10-212015-12-31GlobalCorporate-wide; includes termination of a number of pipeline programs (e.g., TECFIDERA in SPMS, anti-TWEAK in lupus nephritis)USD 85 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge range disclosed as $85M to $95M (value field shows lower bound). Cash payments expected of $115M to $120M, including previously accrued incentive compensation; substantially all incurred and paid by end of 2015. Expected to reduce annual run-rate operating expenses by approximately $250 million. Absolute headcount number not disclosed; only the 11% workforce reduction percentage.
2015-09-30acquisition_additioncompleted2015-02-122015-02-12Research & Development (clinical-stage neuropathic pain programs)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Biogen states it retained the services of key Convergence employees; no headcount figure disclosed. Acquisition occurred in Q1 2015 but is reported in this filing's nine-month period.
2015-09-30restructuringannounced11%2015-10-212015-12-31GlobalCorporate and Pipeline ProgramsUSD 90 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced corporate restructuring including termination of pipeline programs and 11% workforce reduction. Expected charge range $85M-$95M; cash payments $115M-$120M. Substantially all amounts to be incurred and paid by end of 2015.
2015-06-30acquisition_additioncompleted2015-02-12business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Convergence Pharmaceuticals; retained services of key employees. Specific headcount not disclosed.
2015-03-31acquisition_additioncompleted2015-02-122015-02-12United KingdomResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filing states Biogen retained the services of key Convergence employees upon the February 12, 2015 closing, but discloses no headcount figure.
2015-03-31acquisition_additioncompleted2015-02-12business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Convergence Pharmaceuticals; retained services of key employees. Specific headcount not disclosed.
2014-12-31acquisition_additionannounced2015-01-11United KingdomResearch and DevelopmentUSD 200 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned acquisition of clinical-stage biopharmaceutical company announced after fiscal year-end; upfront payment of $200.0 million plus up to $475.0 million in contingent milestones. Headcount not disclosed.
2014-12-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31acquisition_additioncompleted2013-04-022013-04-02GlobalMultiple sclerosis franchise (TYSABRI)USD 3,250 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of full TYSABRI rights from Elan for $3.25 billion upfront; accounted for as an asset acquisition and the filer states no employees were acquired, so no headcount addition is quantified.
2013-12-31restructuringcompleted20102012-12-31GlobalSales, Research and Development, AdministrativeUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2010 restructuring initiative. As of December 31, 2012, all restructuring charges related to this initiative had been incurred and paid. No restructuring charges were recorded in 2013.
2013-12-31restructuringcompleted20102012-12-31GlobalSales, Research and Development, AdministrativeUSD 0 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2010 restructuring initiative completed. Included 13% workforce reduction. No charges recorded in 2013; all charges incurred and paid by end of 2012.
2013-12-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-30restructuringannounced2013-09-302014-06-30Weston, MassachusettsCorporate HeadquartersUSD 25 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company expects to vacate part of Weston facility in Q4 2013 due to HQ relocation to Cambridge. Charge represents remaining lease obligation net of sublease income. Subleasing begins in first half of 2014.
2013-09-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringcompletedWeston, MassachusettsCorporate HeadquartersUSD 25 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company expects to incur a charge between $20.0 million and $30.0 million in connection with vacating part of Weston facility for HQ relocation to Cambridge. Estimate represents remaining lease obligation net of sublease income.
2013-06-30restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringcompletedUSD 0 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Filing states: 'As of March 31, 2013, all restructuring charges related to our 2010 initiative have been incurred and paid. We no longer have a restructuring liability associated with these initiatives.' No employee count disclosed for the current period.
2013-03-31otherannounced2013-06-30Weston, MassachusettsCorporate HeadquartersUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company expects to vacate part of Weston facility in H2 2013 and incur a charge between $15.0 million to $30.0 million representing remaining lease obligation net of sublease income. No specific headcount reduction disclosed.
2013-03-31restructuringin_progressUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-31restructuringcompleted2010-112012-12-31GlobalSales, research and development, and administrative functionsUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced November 2010 included a 13% workforce reduction (count disclosed in prior-year filings, not restated here); FY2012 restructuring charge was $2.2M with no employee separations quantified for 2012, and the restructuring reserve was fully paid down to zero at 2012-12-31.
2012-12-31acquisition_additioncompleted2012-03-082012-03-08United StatesResearch and development (fibrosis / idiopathic pulmonary fibrosis)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Stromedix, Inc. completed 2012-03-08; purchase price $207.4M including $122.2M contingent consideration. Headcount added through the acquisition was not disclosed.
2012-12-31restructuringcompleted2010-112012-12-31GlobalSales, Research and Development, AdministrativeUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Initiated in November 2010. Included 13% workforce reduction. As of December 31, 2012, substantially all restructuring charges have been incurred and paid. Charge reflects activity in 2012.
2012-12-31acquisition_additioncompleted2012-03-082012-03-08United StatesResearch and Developmentbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Stromedix, Inc. on March 8, 2012. Headcount not explicitly disclosed.
2012-12-31restructuringcompleted2010-112012-12-31WorldwideSales, Research and Development, AdministrativeUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Initiated in Nov 2010. Included 13% workforce reduction. Substantially all charges incurred and paid by Dec 31, 2012.
2012-12-31restructuringin_progressUSD 2,225,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-30restructuringcompletedUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charge incurred in Q3 2012 related to 2010 initiative; substantially all charges from 2010 initiative incurred and paid.
2012-09-30restructuringcompletedUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		YTD charge for 2012 related to 2010 initiative; substantially all charges from 2010 initiative incurred and paid.
2012-09-30restructuringin_progressUSD 803,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressResearch organizationUSD 9 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		July 2012 reorganization of research organization to emphasize early discovery research; estimated cost ~$9.0M to be recorded in Q3 2012. Employee count not disclosed.
2012-06-30restructuringin_progressUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Residual restructuring charges from 2010 initiative: $1.1M in Q2 2012, $1.4M YTD 2012. Filer states substantially all charges from the 2010 initiative have been incurred and paid as of June 30, 2012; no employee counts disclosed.
2012-06-30acquisition_additioncompleted2012-03-082012-03-08United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Stromedix completed March 8, 2012; obtained rights to key employees and STX-100 antibody program. Headcount added not quantified.
2012-06-30restructuringcompletedUSD 1 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charge for the three months ended June 30, 2012. MD&A states substantially all related restructuring charges from 2010 initiative have been incurred and paid.
2012-06-30restructuringannounced2012-07-012012-09-30ResearchUSD 9 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Reorganization of research organization initiated in July 2012. Costs estimated at $9.0 million to be recorded in the third quarter.
2012-06-30restructuringin_progressUSD 1,422,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringcompleted2010-11USD 0 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Residual charge in Q1 2012 for the November 2010 restructuring initiative; filing states substantially all related charges have been incurred and paid. No employee count disclosed.
2012-03-31acquisition_additioncompleted2012-03-082012-03-08United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Stromedix completed 2012-03-08; filing notes acquisition of key employee services but discloses no headcount figure.
2012-03-31restructuringcompleted2010-11-01USD 0 (thousands)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Strategic initiatives announced in Nov 2010. Substantially all charges incurred and paid as of March 31, 2012. Q1 2012 charge was $0.3 million.
2012-03-31restructuringin_progressUSD 283,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-12-31restructuringin_progress13%2010-11-03GlobalSales, research and development, and administrative functionsUSD 19 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2011 activity only: $19.0M charge ($12.8M workforce reduction, $6.2M facility consolidation). Program announced Nov 2010 with 13% workforce reduction; substantially all charges incurred and paid by 2011-12-31. Prior-year $75.2M charge not included.
2011-12-31plant_closurecompleted2010-11-032011-08-31United StatesSan Diego, California facilityrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		San Diego facility sale-leaseback terminated effective 2011-08-31; part of Nov 2010 restructuring initiative. No headcount disclosed.
2011-12-31acquisition_additioncompleted2011-09-062011-09-06Italy and SwitzerlandSales affiliates (Biogen Dompé SRL, Biogen Dompé Switzerland GmbH)USD 153 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase of noncontrolling interests in JV sales affiliates; cash payments of $152.9M plus up to $42.5M contingent consideration. No headcount added disclosed.
2011-12-31restructuringcompleted13%2010-11-012011-12-31GlobalSales, Research and Development, AdministrativeUSD 19 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced November 2010. Included 13% workforce reduction. $19.0M charge in 2011 ($12.8M workforce, $6.2M facility). Substantially all charges incurred and paid by year-end.
2011-12-31restructuringcompleted13%2010-112011-12-31WorldwideSales, Research and Development, AdministrativeUSD 19 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced Nov 2010. 13% workforce reduction. $19.0M charge in 2011 ($12.8M workforce, $6.2M facility). Substantially all charges incurred and paid by year-end.
2011-12-31restructuringin_progressUSD 19,026,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressEmployee Severance [Member]USD 12,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressFacility Closing [Member]USD 6,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-09-30restructuringin_progress2010-11-012011-12-31GlobalSales, research and development, and administrative functionsUSD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced November 2010 includes a completed 13% workforce reduction; no absolute headcount disclosed. $18.4M charged in 9M 2011 (plus $75.2M in Q4 2010); total charges expected not to exceed $100.0M with substantially all remaining charges incurred and paid by end of 2011. Restructuring reserve fell from $66.4M at 2010-12-31 to $2.6M at 2011-09-30.
2011-09-30plant_closurecompleted2010-11-012011-08-31United States (San Diego, California)Facility consolidationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		San Diego facility sale-leaseback terminated effective 2011-08-31 and accounted for as a sale; no significant gain or impairment recognized. No employee count disclosed.
2011-09-30plant_closureannounced2011-07-012013-06-30United States (Weston, Massachusetts)Corporate headquarters relocation to Cambridge, MassachusettsUSD 35 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Leases for two Cambridge office buildings executed July 2011; Weston facility expected to be vacated upon completion (occupancy planned 2H 2013). Company expects an approximately $35.0M charge (remaining Weston lease obligation net of estimated sublease income) plus approximately $25.0M of additional depreciation recognized ratably from Q3 2011. No employee count disclosed.
2011-09-30restructuringin_progress13%2010-11-012011-12-31GlobalSales, Research and Development, AdministrativeUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		13% workforce reduction completed; $18.4M charges incurred in first nine months of 2011. Total charges expected not to exceed $100.0M.
2011-09-30restructuringin_progressUSD 18,390,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressRestructuring Depreciation [Member]USD 6,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressEmployee Severance [Member]USD 12,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringcompleted13%2010-112011-12-31Sales, research and development, and administrative functionsUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Framework for Growth program announced November 2010; 13% workforce reduction reported as completed. Charge shown is net workforce-reduction charge for six months ended 2011-06-30 (includes $2.7M expense offset by $4.4M net favorable revisions in Q2). Total program estimated at ~$100M, with $75.2M incurred in Q4 2010; substantially all charges expected incurred and paid by end of 2011. Absolute headcount affected not disclosed.
2011-06-30plant_closurecompleted2010-112011-12-31United StatesFacilities — San Diego, California and Massachusetts sitesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility-consolidation component of the same November 2010 program: San Diego facility vacated and certain Massachusetts facilities consolidated as of 2011-06-30. Charge shown is facility-consolidation charge for six months ended 2011-06-30, inclusive of additional depreciation. San Diego sale-leaseback arrangement terminates 2011-08-31. No employee count disclosed for this component.
2011-06-30restructuringcompleted2010-11United StatesRITUXAN oncology and rheumatology sales forceMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As part of the November 2010 restructuring, Biogen Idec and Genentech eliminated the RITUXAN oncology and rheumatology sales force in Q4 2010, with Genentech assuming U.S. sales and marketing. Headcount affected not disclosed; no separate charge quantified.
2011-06-30otherannounced2011-07-142013-06-30United StatesCorporate headquarters and commercial operations (Weston, MA relocation to Cambridge, MA)USD 35 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter event: leases executed 2011-07-14 for two Cambridge, MA buildings (~500,000 sq ft) as future HQ, occupancy planned 2H 2013. Company expects to vacate the Weston, MA facility, incurring an estimated ~$35.0M charge (remaining lease obligation net of estimated sublease income) plus ~$25.0M of additional depreciation. No employee counts or relocation figures disclosed.
2011-06-30restructuringin_progress13%2010-11-012011-12-31GlobalSales, Research and Development, AdministrativeUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		13% workforce reduction completed. $16.6M charges incurred in six months ended June 30, 2011. Total expected charges ~$100M.
2011-06-30restructuringin_progressUSD 16,587,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressRestructuring Depreciation [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressEmployee Severance [Member]USD 10,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progress2010-11-012011-12-31GlobalSales, research and development, and administrative functionsUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced November 2010 includes a 13% workforce reduction, R&D program terminations, and facility consolidation. Q1 2011 charge of $16.6M ($12.1M workforce, $4.5M facility); $75.2M recognized in Q4 2010; total expected ~$110M. No absolute headcount affected disclosed.
2011-03-31plant_closurein_progress2010-10-012011-08-31San Diego, California, United StatesFacility consolidationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		San Diego facility sold October 2010 with 15-month leaseback; lease terminated effective August 31, 2011. Facility consolidation charge of $4.5M in Q1 2011 includes $3.5M additional depreciation. No employee count disclosed.
2011-03-31restructuringin_progress13%2010-11-012011-12-31GlobalSales, Research and Development, AdministrativeUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		13% workforce reduction substantially completed; $16.6M charge in Q1 2011 ($12.1M workforce, $4.5M facility). Total expected charges ~$110M.
2011-03-31restructuringin_progressUSD 16,587,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressRestructuring Depreciation [Member]USD 3,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressFacility consolidation [Member]USD 4,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressWorkforce reduction [Member]USD 12,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-12-31restructuringin_progress13%2010-11-032011-12-31WorldwideSales, research and development and administrative functionsUSD 67 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction component of the Framework for Growth program; 13% headcount reduction (no absolute count disclosed). $67.2M of the ~$90M expected workforce-reduction charge recognized in FY2010; $60.6M reserve remained at year-end. Program announced 2010-11-03, substantially complete by end of 2011.
2010-12-31plant_closurein_progress2010-11-032011-12-31United States (San Diego, California; Massachusetts)Research, development and administrative facilitiesUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility consolidation component: closing the San Diego site (sold 2010-10-01, leaseback terminated effective 2011-08-31) and consolidating Massachusetts facilities. $8.0M recognized in FY2010 of ~$20M expected total; includes additional depreciation from shortened asset lives. No headcount attributed to this component.
2010-12-31reduction_in_forcecompleted2010-11-032010-12-31United StatesRITUXAN oncology and rheumatology sales forceItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Elimination of the RITUXAN oncology/rheumatology sales force in Q4 2010, with Genentech assuming sole U.S. sales and marketing responsibility. No headcount or separate charge disclosed; part of the same 2010-11-03 restructuring program.
2010-12-31acquisition_additioncompleted2010-12-172010-12-17SwitzerlandResearch and development (neurology antibody discovery)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Panima Pharmaceuticals AG completed 2010-12-17 for $32.5M cash plus up to $395.0M contingent milestones; key employees acquired but no headcount figure disclosed.
2010-12-31restructuringin_progress13%2010-11-032011-12-31GlobalSales, Research and Development, AdministrativeUSD 110 (millions)Item 1 Business - Framework for Growth
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		13% workforce reduction impacting sales, R&D, and administrative functions. Total expected charges of $110 million. Substantially completed by end of 2011.
2010-12-31restructuringin_progress13%2010-11-032011-12-31WorldwideSales, Research and Development, AdministrativeUSD 110 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced Nov 3, 2010. 13% workforce reduction. Total expected charges $110M ($90M workforce, $20M facility). $75.2M recognized in 2010. Substantially completed by end of 2011.
2010-12-31restructuringin_progressUSD 75,153,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressFacility consolidation [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressWorkforce reduction [Member]USD 67,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressWorkforce reduction [Member] / Award Modification [Member]USD 6,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2008-12-31restructuringcompleted2008-12-31GlobalCorporate / legal structure and organizational functionsUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2008 restructuring costs of $5.0M, primarily for reorganization of legal structure and consolidation of certain organizational functions; included in R&D and SG&A expense. No employee count disclosed. No material remaining accruals at year-end.
2008-12-31restructuringcompleted2008-12-312008-12-31GlobalDomestic and International OperationsUSD 5 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In the fourth quarter of 2008, the company completed a reorganization of domestic and international operations, including movement of personnel and supply chain restructuring. Total severance and restructuring costs were $5.0 million. No specific employee count was disclosed.
2008-12-31restructuringcompleted2008-12-312008-12-31GlobalDomestic and International OperationsUSD 5 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Reorganization of domestic and international operations, movement of personnel, and restructuring of supply chain. No specific employee count disclosed.
2007-12-31acquisition_additioncompleted2007-01-012007-01-31United StatesResearch & DevelopmentUSD 18 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Syntonix Pharmaceuticals, Inc. completed January 2007; headcount added not disclosed. $18.4M IPR&D charge recorded.
2007-12-31divestiture_reductioncompleted2007-12-012007-12-31United StatesOncology (ZEVALIN product line)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of U.S. ZEVALIN rights to Cell Therapeutics completed December 2007; headcount removed not disclosed.
2007-12-31restructuringcompleted2007-12-31United StatesCorporateUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2007 restructuring costs of $1.8M primarily related to the Syntonix acquisition and ZEVALIN divestiture; no material remaining accruals at year-end. Employees affected not disclosed.
2007-12-31restructuringcompleted2007-01-012007-12-31GlobalVariousUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Severance and other restructuring costs totaled $1.8 million in 2007, primarily related to the Syntonix acquisition and the ZEVALIN divestiture. No specific employee count disclosed for 2007 actions.
2007-12-31restructuringcompleted2007-01-012007-12-31GlobalVariousUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance and other restructuring costs totaled $1.8 million in 2007, primarily related to the Syntonix acquisition and the ZEVALIN divestiture. No material remaining accruals at year-end.
2007-12-31acquisition_additioncompleted2007-01-012007-12-31United StatesR&DMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Syntonix Pharmaceuticals, Inc. in January 2007 added R&D personnel and programs. Specific headcount not disclosed.
2007-09-30acquisition_additioncompleted2007-01-01Waltham, MassachusettsResearch and DevelopmentUSD 44 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% of Syntonix Pharmaceuticals, Inc. in January 2007. Headcount not disclosed. Purchase price $44.4 million.
2007-09-30acquisition_additioncompleted2007-08-01GlobalResearch and DevelopmentUSD 50 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement with Cardiokine Biopharma LLC became effective in August 2007. Consolidated results under FIN 46. Headcount not disclosed. Upfront payment $50.0 million.
2007-09-30othercompleted2007-06-272007-07-02GlobalCorporateUSD 2,991 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Completed tender offer repurchasing 56,424,155 shares for $2,990.5 million. Not a workforce reduction action, but a material capital allocation event disclosed in the period.
2007-06-30acquisition_additioncompleted2007-01-31United States (Waltham, Massachusetts)Research and DevelopmentUSD 0 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Syntonix Pharmaceuticals for $44.4 million; no employee count disclosed. $0.3 million of severance was accrued in the six months ended 2007-06-30 as a result of the acquisition; an assembled-workforce intangible of $0.7 million was also recognized.
2007-06-30divestiture_reductionin_progress2006-09-30ZEVALIN product lineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company began executing a plan to divest the ZEVALIN product line during Q3 2006; MD&A notes reduced domestic sales and marketing effort. No headcount reduction quantified in this filing.
2007-06-30acquisition_additioncompleted2007-01-01Waltham, MassachusettsResearch and DevelopmentUSD 0 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Syntonix Pharmaceuticals, Inc. in January 2007. Headcount not disclosed. $0.3 million in severance charges accrued in the six months ended June 30, 2007.
2007-03-31acquisition_additioncompleted2007-01-01Waltham, MassachusettsResearch and DevelopmentUSD 0 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% of Syntonix in January 2007. Headcount not disclosed. $0.3 million severance charges accrued in Q1 2007.
2006-12-31acquisition_additioncompleted2006-06-152006-06-15SwitzerlandResearch and DevelopmentUSD 207 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Fumapharm AG; headcount added not disclosed; charge is acquired in-process R&D for BG-12, not severance
2006-12-31acquisition_additioncompleted2006-05-012006-05-01United States (California)Research and DevelopmentUSD 123 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Conforma Therapeutics; headcount added not disclosed; charge is acquired in-process R&D for CNF2024, not severance
2006-12-31restructuringcompleted2006-05-012006-12-31United StatesResearch and DevelopmentUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance costs incurred in connection with the Conforma acquisition during 2006; headcount affected not disclosed
2006-12-31divestiture_reductionin_progress2006-07-012006-12-31Not disclosedZEVALIN product lineUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount reductions related to the planned divestiture of the ZEVALIN product line, begun in Q3 2006; headcount affected not disclosed
2006-12-31divestiture_reductioncompleted2006-04-012006-04-30Not disclosedAMEVIVE product lineMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Worldwide rights to AMEVIVE sold to Astellas in April 2006; associated headcount not disclosed
2006-12-31restructuringcompleted6502005-092005-12-31WorldwideVariousUSD 31 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2005 Strategic Plan implemented in Sept 2005; reduced workforce by approx 17% (650 positions). Charges of $31.4M recorded in 2005. Subsequent 2006 charges of $2.9M related to Conforma acquisition and ZEVALIN divestiture headcount reductions.
2006-12-31restructuringcompleted20062006-12-31WorldwideVariousUSD 3 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2006 restructurings associated with acquisitions (Conforma) and planned dispositions (ZEVALIN). $1.2M severance for Conforma; $1.7M headcount reductions for ZEVALIN.
2006-12-31restructuringcompleted65017%2005-092005-12-31WorldwideVarious (management layers and staff functions)USD 31 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2005 Strategic Plan implemented in Sept 2005; substantially completed by end of 2005. Charge includes severance and other termination costs.
2006-12-31restructuringcompleted20062006-12-31WorldwideConforma acquisition and ZEVALIN divestitureUSD 3 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2006 Restructurings: $1.2M severance for Conforma acquisition; $1.7M headcount reductions for ZEVALIN disposition.
2006-09-30acquisition_additioncompleted2006-06-15SwitzerlandResearch and Development / CommercialUSD 1 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Fumapharm AG completed June 15, 2006; no headcount disclosed. $1.2M severance relates to Conforma, not Fumapharm.
2006-09-30acquisition_additioncompleted2006-05-01United States (California)Research and DevelopmentUSD 1 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Conforma Therapeutics completed May 2006; approximately $1.2M in severance costs incurred. No headcount disclosed.
2006-09-30divestiture_reductioncompleted2006-04-01GlobalAMEVIVE product lineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide rights to AMEVIVE sold to Astellas Pharma US in April 2006 for $59.8M. No headcount impact disclosed.
2006-09-30divestiture_reductionin_progress2006-07-01GlobalZEVALIN product lineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to divest ZEVALIN product line initiated during Q3 2006. No headcount impact disclosed.
2006-09-30plant_closurecompleted2006-02-01United States (Oceanside, California)Clinical manufacturing (NICO facility)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		NICO clinical manufacturing facility sold to Genentech in February 2006 for $29.0M. Prior impairment charges of $28.0M recorded in 2005. No headcount disclosed.
2006-09-30restructuringin_progress2005-09-01GlobalEnterprise-wideUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2005 strategic plan restructuring; $31.4M total charges recorded in 2005. Remaining liability of $6.1M at Sept 30, 2006. No employee count disclosed. $2.0M additional costs incurred YTD 2006, none in Q3.
2006-09-30restructuringin_progress2005-01-01USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs incurred during 2006 related to comprehensive strategic plan initiated in 2005. Includes severance and other employee termination costs. Employee count not disclosed.
2006-09-30restructuringcompleted2006-05-01CaliforniaUSD 1 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs incurred in connection with the acquisition of Conforma Therapeutics Corporation in May 2006. Employee count not disclosed.
2006-06-30restructuringin_progress2005-09Company-wideUSD 2,027 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program under the comprehensive strategic plan announced September 2005; charges consist mainly of severance, termination benefits, outplacement and related items. $771 thousand incurred in Q1 2006 and $1,256 thousand in Q2 2006 (six-month total shown); remaining liability of $7,554 thousand at 2006-06-30. No employee counts disclosed; six-month charge includes approximately $1.2 million of Conforma-related severance also shown separately below. Filer states further restructuring charges may occur in future periods.
2006-06-30restructuringin_progress2006-05United StatesConforma Therapeutics Corporation (oncology R&D) — acquisition-relatedUSD 1,200 (thousands)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance costs incurred in connection with the May 2006 Conforma asset acquisition; amount is included in the Note 16 restructuring rollforward (do not add to the program total above). No affected-employee count disclosed.
2006-06-30restructuringin_progress2005-09-01USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred in Q2 2006 related to the comprehensive strategic plan initiated in 2005. Includes severance and employee termination costs. Employee count not disclosed.
2006-06-30restructuringin_progress2006-05-01USD 1 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs incurred in connection with the acquisition of Conforma. Employee count not disclosed.
2006-03-31restructuringin_progress65017%2005-09WorldwideCompany-wide (all functions, departments and sites)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Comprehensive strategic plan announced September 2005; workforce reduced by approximately 17%, or about 650 positions, substantially implemented. Remaining severance and other liability was $9.6 million at 2006-03-31 (costs incurred during 2006: $0.8 million; paid/settled through 2006-03-31: $8.6 million). Total program charge not disclosed in this filing; no completion date stated.
2006-03-31divestiture_reductioncompleted2006-042006-04WorldwideImmunology commercial (AMEVIVE sales force)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide rights to AMEVIVE sold to Astellas for $60.0 million including inventory; MD&A attributes lower AMEVIVE selling costs to a reduced sales force tied to the divestiture. Number of employees affected not disclosed. Biogen Idec will continue to manufacture and supply AMEVIVE.
2006-03-31divestiture_reductioncompleted2006-022006-02United States (Oceanside, California)Clinical manufacturing (NICO facility)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		NICO clinical manufacturing facility sold to Genentech for $29.0 million in February 2006; no additional loss recorded. Headcount associated with the facility not disclosed.
2006-03-31acquisition_additionannounced2006-05-022006-06-30United StatesResearch and development (heat shock protein 90 programs)USD 150 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement and Plan of Merger with Conforma Corporation signed 2006-05-02; initial payment of $150 million plus up to $100 million in development milestones. Expected to close in Q2 2006. Headcount to be added not disclosed.
2006-03-31restructuringin_progress6502005-09-01WorldwideCompany-wideUSD 9,604 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining liability at March 31, 2006 includes $9.5 million for severance and $62 thousand for other costs. Program initiated in Q3 2005 reduced workforce by approx 17%.
2005-12-31restructuringcompleted65017%2005-09-012005-12-31WorldwideCompany functions, departments and sitesUSD 31 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Comprehensive strategic plan begun September 2005; ~17% workforce reduction (~650 positions), substantially implemented by end of 2005. Charges: $20.0M in R&D, $11.4M in SG&A. Remaining liability $17.5M at year-end. Includes $7.1M charge for retirement of former Executive Chairman.
2005-12-31plant_closurecompleted2005-06-232005-06-23Oceanside, CaliforniaLarge-scale biologics manufacturing (NIMO facility)USD 84 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		NIMO facility sold to Genentech for $408.1M consideration; loss of $83.5M. Employee headcount impact not disclosed.
2005-12-31divestiture_reductionannounced2005-09-01United StatesAMEVIVE product franchiseItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company seeking to divest AMEVIVE as part of strategic plan; assets held for sale include $8.0M intangibles and $5.4M PP&E. Headcount impact not disclosed.
2005-12-31plant_closureannounced2006-02-01Oceanside, CaliforniaNICO clinical manufacturing facilityUSD 28 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		NICO facility sold to Genentech in February 2006 (subsequent to fiscal year-end); $28.0M impairment recorded in 2005 as held for sale. Headcount impact not disclosed.
2005-12-31restructuringcompleted65017%2005-09-012005-12-31WorldwideAll functionsUSD 31 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Part of comprehensive strategic plan announced in September 2005. Adjustments substantially implemented by end of 2005. Charges include severance, outplacement, bonuses, and write-downs of research assets.
2005-12-31restructuringcompleted65017%2005-092005-12-31WorldwideAll functionsUSD 31 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Comprehensive strategic plan implemented in September 2005 resulting in reduction of workforce by approximately 17%, or approximately 650 positions worldwide. Adjustments substantially implemented by end of 2005. Total charges of $31.4 million include severance and other employee termination costs.
2005-09-30restructuringin_progress65017%2005-09-082005-12-31WorldwideCompany-wide (all functions, departments and sites)USD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Comprehensive strategic plan announced September 2005; approximately 17% workforce reduction, about 650 positions. Charges incurred at September 8, 2005 totaled $27.2M ($19.6M in R&D, $7.6M in SG&A); $24.8M remained accrued at September 30, 2005. Announcement date reflects earliest disclosed charge date; exact announcement day not stated.
2005-09-30divestiture_reductioncompleted3342005-06-232005-08-16Oceanside, California, United StatesNIMO large-scale biologics manufacturing facilityMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Genentech purchased the NIMO facility on June 23, 2005; 334 employees were offered at-will employment by Genentech and remained employed by the company through August 16, 2005.
2005-09-30divestiture_reductionannounced2005-09-302006-03-31WorldwideAMEVIVE (alefacept) product franchiseMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company announced in September 2005 it will seek to divest AMEVIVE, expected in the first quarter of 2006; associated headcount impact not quantified in the filing.
2005-09-30restructuringin_progress65017%2005-09-012005-12-31WorldwideAll functionsUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of workforce by approximately 17% as part of comprehensive strategic plan. Charges include severance, health benefits, outplacement, bonuses, and write-downs of research assets.
2005-09-30plant_closurecompleted3342005-06-232005-08-16Oceanside, CaliforniaManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of 334 employees working at NIMO facility following sale to Genentech. Employees continued to be employed by Biogen Idec through August 16, 2005.
2005-06-30divestiture_reductioncompleted3342005-06-232005-08-16Oceanside, California, United StatesManufacturing (NIMO large-scale biologics facility)USD 76 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Genentech purchased the NIMO facility on 2005-06-23. Biogen Idec terminated 334 employees; Genentech offered at-will employment to them. Employees remained employed by Biogen Idec through 2005-08-16, with Genentech reimbursing related costs. Charge includes $66.1M write-down and $9.5M transaction costs.
2005-06-30plant_closurecompleted3342005-06-232005-08-16Oceanside, CaliforniaManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Following the sale of the NIMO facility to Genentech, 334 employees were terminated or offered employment by Genentech. Biogen Idec continued to employ these individuals through August 16, 2005, with Genentech reimbursing related costs.
2004-12-31restructuringin_progressSan Diego, CaliforniaMerger integration — San Diego facilitiesUSD 4 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance obligations for certain employees affected by the Biogen merger; approximately $0.4 million accrual remained at year-end 2004. Headcount not disclosed.
2004-12-31restructuringin_progressEuropeEuropean headquarters relocationUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs accrued in 2004 for relocation of European headquarters; $1.1 million liability remained at December 31, 2004. Headcount not disclosed.
2004-12-31restructuringin_progressCambridge, MassachusettsMerger integration — Cambridge facilitiesUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional 2004 charges for severance obligations of employees affected by the merger in Cambridge facilities; $0.2 million liability remained at year-end. Headcount not disclosed.
2004-12-31otherannounced2005-02-28GlobalCommercial — TYSABRI (with Elan)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary suspension of TYSABRI marketing and commercial distribution announced February 2005; dosing suspended in clinical studies. No workforce reduction quantified.
2004-12-31otherannounced2005-03-31Hillerod, DenmarkManufacturing — fill-finish component discontinuedUSD 7 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision not to proceed with fill-finish component of Hillerod facility; capitalized engineering costs to be written off to R&D expense in Q1 2005. No headcount impact disclosed.
2004-12-31restructuringcompleted2004-01-012004-12-31San DiegoGeneralUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges related to severance obligations for certain employees affected by the Merger in San Diego facilities. Remaining accrual of $0.4 million at year-end.
2004-12-31restructuringin_progress2004-01-01EuropeGeneralUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring costs related to the relocation of European headquarters. Remaining liability of $1.1 million at year-end.
2004-12-31restructuringcompleted2003-11-122004-12-31CambridgeGeneralUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Additional charges accrued in 2004 for severance obligations for employees affected by the Merger in Cambridge facilities. Remaining liability of $0.2 million at year-end.
2004-12-31restructuringcompleted2004-01-012004-12-31San DiegoUSD 4 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Charges of $4.4 million related to severance obligations for certain employees affected by the Merger in San Diego facilities.
2004-12-31restructuringin_progress2004-01-01EuropeUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Accrued approximately $2.3 million of restructuring costs related to the relocation of European headquarters. Remaining liability was $1.1 million at year-end.
2004-12-31restructuringin_progress2003-11-13CambridgeUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Accrued an additional $1.0 million of charges in 2004 for severance obligations for certain employees affected by the Merger in Cambridge facilities. Remaining liability was $0.2 million at year-end.
2004-09-30restructuringin_progressSan Diego, CaliforniaOperationsUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance charges for certain employees affected by the Merger; $0.4M in Q3, $4.4M YTD; remaining accrual ~$1.0M at quarter-end.
2004-09-30restructuringin_progressCambridge, MassachusettsOperationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional severance charges accrued in 2004 ($0.2M Q3, $1.0M YTD) on top of $2.1M accrued in 2003; remaining accrual ~$1.6M at quarter-end.
2004-09-30restructuringin_progressEuropeOperationsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		European headquarters relocation restructuring; $10.2M accrued in 2003 plus $1.3M additional in 2004 YTD; payments of $10.5M YTD; remaining accrual ~$1.0M at quarter-end.
2004-09-30restructuringin_progress2003-01-01EuropeGeneralUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters. Accrued additional $0.3M in Q3 2004; $1.0M remaining accrual.
2004-09-30restructuringin_progress2003-01-01Cambridge, MAGeneralUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for certain employees. Accrued additional $0.2M in Q3 2004; $1.6M remaining accrual.
2004-09-30restructuringin_progress2004-01-01San Diego, CAGeneralUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for certain employees affected by Merger. Recorded $0.4M charge in Q3 2004; $1.0M remaining accrual.
2004-06-30restructuringin_progress2003-12-31EuropeCorporate / European headquarters relocationUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring for European HQ relocation; $10.2M accrued in 2003 plus $1M additional in H1 2004; $5.2M paid in H1 2004; ~$6M remaining accrual at 2004-06-30. No employee count disclosed.
2004-06-30restructuringin_progress2003-12-31United States — Cambridge, MACambridge facilitiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for certain Cambridge employees; $2.1M accrued in 2003 plus $0.8M additional in H1 2004; ~$2.2M remaining accrual at 2004-06-30. No employee count disclosed.
2004-06-30restructuringin_progress2004-01-01United States — San Diego, CASan Diego facilitiesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for certain San Diego employees affected by the Merger; $4M charged in H1 2004 ($0.8M in Q2); ~$1.8M remaining accrual at 2004-06-30. No employee count disclosed.
2004-06-30restructuringin_progress2003-12-31EuropeUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued additional $1 million in first six months of 2004 for European headquarters relocation. Remaining accrual approx $6 million.
2004-06-30restructuringin_progress2003-12-31CambridgeUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued additional $0.8 million in first six months of 2004 for severance obligations for certain employees. Remaining accrual approx $2.2 million.
2004-06-30restructuringin_progress2004-01-01San DiegoUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recorded charges of $4 million in first six months of 2004 for severance obligations for certain employees. Remaining accrual approx $1.8 million.
2004-03-31restructuringin_progressEuropeCorporate (European headquarters relocation)USD 9 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Accrued in 2003; $1.0M added and $2.0M paid in Q1 2004, leaving ~$9.2M accrual at 2004-03-31. No employee count disclosed.
2004-03-31restructuringin_progressUnited States (Cambridge, MA)Corporate (Cambridge facilities)USD 3 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual of $2.1M recorded in 2003 plus $0.8M additional charge in Q1 2004; ~$2.7M remaining accrual at 2004-03-31. No employee count disclosed.
2004-03-31restructuringin_progressUnited States (San Diego, CA)Corporate (San Diego facilities; merger-related)USD 3 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		$3.2M severance charge recorded in Q1 2004 for certain employees affected by the merger; ~$2.8M remaining accrual at 2004-03-31. No employee count disclosed.
2004-03-31restructuringin_progressEuropeUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional accrual for relocation of European headquarters.
2004-03-31restructuringin_progressCambridgeUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for severance obligations for certain employees in Cambridge facilities.
2004-03-31restructuringin_progressSan DiegoUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges for severance obligations for certain employees in San Diego facilities.
2003-12-31acquisition_additioncompleted2003-06-202003-11-12GlobalAll functionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger completed 2003-11-12; Biogen, Inc. became a wholly owned subsidiary. Filer does not disclose headcount added through the acquisition.